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P = amino protecting group 
R l - R3 = amino acid sidechains 
R4  = alkyl
It was aniticipated that a compound such as 1 would be resistant to enzymatic 
degradation, since incorporation of a reduced amide bond in place of an amide at a 
point of cleavage in a biologically active peptide is known to produce a protease 
enzyme inhibitor by mimicking the tetrahedral transition state for amide bond 
hydrolysis, which is itself resistant to hydrolysis.
The conformation of such a compound was also of interest since molecular 
modelling studies suggest that reduction of certain amide bonds in a peptide chain 
causes the peptide to adopt a P turn structure.
Synthetic routes to compound 1 via amide reduction, Mitsunobu alkylation, 
reductive amination of N-(t-butoxycarbonyl)amino aldehydes and tosylate 
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DCU: 1 ,3-dicyclohexylurea 
DEAD: diethyl azodicaiboxylate














PMA: phosphomolybdic acid 
py: pyridine 
q: quartet
Red-Al: sodium bis(2-methoxyethoxy)aluminium hydride 
s: singlet 
t: triplet
TFA: trifluoroacetic acid 
THF: tetrahydrofuran
Tic: 1 ,2 ,3 ,4-tetrahydroisoquinoline-3-carboxylic acid 
TIPA: N, N, N \ N’-tetraisopropylazodicarboxamide 
TMAD: N, N, N', N’-tetramethylazodicarboxamide 
TMSQ: chlorotrimethylsilane
Tpi: 2 ,3 ,4 ,9-tetrahydro-1 H-pyrido-[3,4-6]indole-3-carboxylic acid 
Ts: p-toluenesulphonyl 
TsCl: p-toluenesulphonyl chloride 
Z: N-benzyloxycarbonyl
Nomenclature and terminology
IUPAC nomenclature for peptides and peptide analogues is used.
The backbone of a homomeric, homodetic peptide is composed of three 
repeating units: the amide nitrogen, the a-carbon and the amide carbonyl (Figure 1). 
The unit in Figure 1 is referred to as an amino acid residue.
The symbol "y" signals the absence of the amide bond. Within the brackets 
that follow is specified the structure that replaces the amide group, e.g. Figure 2. The 
replacing unit for the amide bond is "CH2 NH"; the nomenclature symbol is
"y[CH2NH]".
Figure 2. Alay[CH2NH]Ala
The following terms are used in this thesis: 
agonist: a molecule that binds to a receptor and produces an effect; 
antagonist or inhibitor a molecule that binds to a receptor and prevents the receptor 
from transmitting a signal;







A host of bioactive peptides have been discovered in the last 20 years. Turn 
structures have been proposed and implicated in the bioactivity of several of these
naturally occurring peptides. Turns are intrinsically polar structures with backbone 
groups that pack together closely and sidechains that project outward. In peptides, 
turns are the conformations of choice for simultaneously optimising both backbone- 
chain compactness (intramolecular nonbonded contacts) and sidechain clustering (to 
facilitate intermolecular recognition).
A turn is defined as a site where the peptide chain reverses its overall direction. 
A p turn contains four amino acid residues. The carbonyl of residue i is hydrogen 
bonded to the NH of residue i+3 (Figure 3).
Figure 3. A p turn.
Table 1 defines the dihedral angles for the eight types of p turns. 1 
Table 1. Dihedral angles in p turns.
i + 1 i + 2
P turn ♦ V ♦ V
Type I -60 -30 -90 0
T ypel’ 60 30 90 0
Typell -60 120 80 0
Type IT 60 -120 -80 0
Type HI -60 -30 -60 -30
Type nr 60 30 60 30
Type IV -60 120 -90 0




1.1 The history of peptide chemistry
'To Emil Fischer we owe the systematic attack on a field of natural 
substances that had previously been avoided by chemists. "2
Emil Fischer is generally regarded as the father of peptide chemistry and this 
quote from Wieland and Bodanszky sums up his place in its history.
Peptide chemistry had its beginnings early this century with the production of 
peptides containing simple amino acids by Fischer and his contemporaries. Without 
the coupling reagents and protecting groups available nowadays, syntheses were 
laborious.
In former times the synthetic difficulties were alleviated somewhat by the 
discovery of the benzyloxycarbonyl protecting group by Bergmann and Zervas in
1932,3 allowing the use of polyfunctional amino acids. The synthesis of small 
peptides was now feasible and glutathione, a naturally occurring small peptide was 
synthesised by Harington and Mead in 1935.4 The synthesis, eighteen years later, of 
the octapeptide hormone, oxytocin by du Vigneaud et a l$  is regarded as a major 
breakthrough in peptide chemistry. The next formative step occurred when 
Bodanszky and his co-workers, in 1967, now with a vast array of protecting groups 
and reagents at hand, synthesised the 27-residue sectretin peptide by solution phase 
stepwise addition methodsA?
Wieland described the advances in peptide chemistry in the following way: 
"... the synthesis of glutathione opened the door to peptide synthesis a crack, and the 
synthesis of oxytocin pushed the door wide open."8 Grant^ extends this analogy, 
saying that the development of solid phase peptide synthesis by Merrifield in 1963 ^  
"blew the door off its hinges".
The introduction of solid phase techniques made the synthesis of large 
peptides feasible for the first time. The area has been expanding ever since and now, 
fully automated peptide synthesisers, which need neither the intervention nor the
presence of any operator are available and these are capable of producing vast 
numbers or "libraries" of peptides in a matter of days.
In recent years there has been a great deal of interest in the field of 
combinatorial chemistry with the recognition that it could revolutionise the drug 
discovery process. One of the greatest difficulties in this process is finding lead 
compounds and it is here that combinatorial chemistry is potentially of tremendous 
value. Initially, only peptide and oligonucleotide libraries were available for 
screening, but recently there has been a move towards the synthesis of libraries of 
small organic compounds, with the attraction that more and more typical organic 
reactions can be carried out with substrates attached to solid supports. Libraries of 
benzodiazepines,H pyrrolidines, 12 p-carbolines,13 phosphoram idates^ and 
piperazinedioneslS  have been synthesised. There is even a report of the 
combinatorial synthesis of chiral phosphine ligands for screening in a catalytic 
asymmetric hydrogenation reaction. 16
1.2 Bioactive peptides
Peptides represent the largest class of hormonal substances 1? and are thus 
essential to virtually every biochemical process. * 8 Table 1.1 gives some examples 
of peptide hormones, which are among the most biologically active compounds 
known, with doses in the picomole range often producing activity, and the effects
they produce. 19,20
Table 1.1 Peptide hormones.
Hormone Effect
Angiotensin II contracts smooth muscle and constricts 
blood vessels
Bradykinin causes contraction of uterine, some 
intestinal and bronchial smooth muscle 
and vasodilation
Cholecystokinin-pancreozymin stimulates pancreatic secretion and 
contracts the gallbladder
ap-Corticotropin stimulates adrenal synthesis and release 
of corticosteroids
Eledoisin contracts smooth muscle and causes 
strong peripheral vasodilation
Endothelin-1 has a blood vessel contracting action 10 
times stronger than angiotensin II
Gastrin I stimulates secretion of acid and pepsin in 
the stomach
Oxytocin contracts the uterus
Somatostatin inhibits the release of growth hormone by 
the pituitary gland
Substance P triggers contraction of the smooth 
muscles of the respiratory, the 
gastrointestinal and the urogenital tract 
and is a potent stimulator for the 
secretion of saliva, pancreatic juice and 
bile
1.3 Why modify?
Since peptides influence such a multitude of physiological processes, they 
provide an attractive starting point for drug discovery. However, bioactive peptides 
themselves cannot be administered as drugs for a number of reasons:^
1. susceptibility to proteolysis;
2. poor absorption after oral ingestion as a result of
(a) their comparatively high molecular mass e.g. oxytocin, a small peptide 
hormone has MW 1008 whereas dexamethasone, a large steroid drug has MW 
382,19 or
(b) the lack of specific transport systems, 
or both;
3. metabolism by the liver and rapid excretion through the kidneys and
4. undesired side effects caused by interaction of the conformationally flexible 
peptides with various receptors.
These problems do not arise with endogenous neuropeptides or peptide 
hormones. One reason for this is that they are often released in a pro-peptide form 
which is cleaved to the biologically active form. For example, in the case of 
endothelin-1, the initially released preproendothelin, containing 203 amino acid 
residues is cleaved to give proendothelin (or "big endothelin"), containing 39 amino 
acid residues. This, in turn, is cleaved by endothelin converting enzyme to give 
endothelin-1.20
Endogenous peptides are released, whether in a pro-form or in their 
biologically active form, close to their site of action and made available to their 
receptors at the precise moment of physiological need. After exerting a short and 
intense effect, they are rapidly degraded into their non-toxic, constituent amino 
acids.21
The problem with administration of a peptide drug is that the site of 
administration is often far away from the site of action, so that transport through one
or more anatomical barriers is required and the possibility exists that the peptide 
might interact with the wrong receptor, thereby producing an undesired side effect.
1.4 Modifications
Thus, the need to modify peptides is evident and work has been carried out 
towards this end for many years now. In his review paper,22 Spatola states, "Almost 
certainly the initial impulse of most bioorganic chemists following the 1953 
announcement of the characterisation and synthesis of the peptide hormone oxytocin 
by Vincent du Vigneaud and co-workers, was a desire to introduce structural 
modifications into the parent compound and to determine the resulting biological 
consequences."
Indeed, within several years, deaminooxytocin (oxytocin minus the N- 
terminal function), which is almost twice as potent as oxytocin itself, had been 
synthesised.23
Initially, the modifications carried out were comparatively simple, 19 with 
only the aim of improving on the potency of the native peptide in mind. The first 
question to be addressed was: what length of peptide chain is necessary for activity? 
This could be determined in the course of synthetic work since each intermediate 
fragment obtained was tested for activity in the standard assays before completion of 
the peptide sequence. In the case of cholecystokinin-pancreozymin, the synthetic 
octapeptide,24 corresponding to the carboxy terminal sequence, was found to be 
even more potent in eliciting the typical responses than the native hormone.
Chain extension work was also carried out and in the case of bradykinin, 
extension at the amino terminal was found to produce mostly active analogues, some 
being more active than bradykinin itself.25,26
Shortening of the peptide chain by omission of residues from within the 
sequence or lengthening the peptide chain by intercalation of an amino acid residue 
within the sequence causes a dramatic overall change in the peptide chain and so,
perhaps not surprisingly, such "frame shifts" were found to lead to complete or 
almost complete loss of activity.
A popular approach to the modification of peptide structures has been 
replacement of constituent amino acids with others. Where a substitution is made 
for the same amino acid in different positions within the same sequence, interesting 
information can be obtained, regardless of the rationale behind the particular 
substitution. In studies on bovine angiotensin n, replacement of Val^ by leucine 
resulted in little change in activity, whereas replacement of Val^ by leucine 
decreased the potency by 75%.27 Nowadays, D-amino acids are routinely 
substituted for L-amino acids as stereochemical probes.
Other modifications have included terminal a-amino acylation,28»29 
oxidation of methionine to the sulphoxide or sulphone,30 methylation or ethylation 
of phenolic hydroxyl groups^! and N-methylation of amide bonds.32
1.5 Modification of the peptide backbone
The next obvious point of modification was the peptide backbone itself.22 
The general topic of backbone replacements was partially presaged by Rudinger^ 
but only comparatively recently, with the increasing sophistication of synthetic 
techniques, has this been possible to any appreciable extent
Modification of the peptide backbone has the potential to increase our 
knowledge of peptides to a much greater degree than sidechain replacements etc. by 
beginning to answer some important questions, such as:
1. Does the peptide backbone/amide bond have a functional role?
2. To what extent is the biological activity of the peptide dependant on the 
alignment and stereochemistry of the peptide backbone?
3. What effect does backbone modification have on resistance to proteolysis?
4. What effect does backbone modification have on the rigidity/flexibility of 
the peptide and what are the consequences?
Any peptide analogue involving a peptide backbone modification can be 
termed a "pseudopeptide". Most peptide backbone modifications involve 
replacement of the amide bond with other moieties known as amide bond 
surrogates.^ y ast numbers of units have been used as amide bond replacements in 
biologically active peptides. Table 1.2 gives some examples of the types of amide 
bond surrogates which have been investigated.
Table 12. Examples of amide bond surrogates.
















Such amide bond surrogates are often referred to as amide bond isosteres, 
even although their isosteric nature is neither obvious nor necessarily required for 
biological efficacy. 45
Another term which is commonly used in this field is "peptide mimetic" or 
"peptidomimetic" (the two are interchangeable). M oore^ defines a peptide mimetic 
as a molecule that mimics the biological activity of a peptide but is no longer
peptidic in chemical nature. Giannis and Kolter^O define a peptide mimetic as a
compound that, as the ligand of a receptor, can imitate or block the biological effect 
of a peptide at the receptor level. As the ligand of an enzyme, a peptide mimetic can 
thus serve as substrate or inhibitor.
The term "peptide mimetic" is, therefore, a very broad one, encompassing the 
whole range of compounds from pseudopeptides, containing an amide bond 
surrogate, to compounds without an identifiable amino acid or peptide moiety. 46
1.6 A new family of peptide mimetics
Interest was focussed on a new family of peptide mimetics, 1 (Figure 1.1).
R-i R3
A .  A  ^ o r 4™ "  Y Y  if
r2 o
1
P = amino protecting group 
R l - R3 = amino acid sidechains 
R4  = alkyl 
Figure 1.1.
Compound 1 is effectively a reduced tripeptide, i.e. both of the amide bonds 
have been replaced by reduced amide or "methyleneamino" moieties. The 
methyleneamino moiety has been extensively used as an amide bond surrogate but 
the effects of incorporating more than one consecutive reduced amide link in the 
same compound have hitherto not been investigated.
1.7 The methyleneamino link as an amide bond isostere
Psuedopeptides containing a reduced amide link often act as antagonists in 
biological systems. There are numerous examples in the literature but only a few are 
detailed here.
It is generally accepted that abnormalities of the renin-angiotensin system 
contribute to certain forms of hypertension. The pathway shown in Scheme 1.147 
can be summarised as follows: angiotensinogen is cleaved by the renal acid protease, 
renin to give the decapeptide, angiotensin I. This, in turn, is cleaved by the 
carboxypeptidase, angiotensin converting enzyme, giving the octapeptide 
angiotensin II which is a potent vasoconstrictor. Intervention in this pathway 
provides a means of controlling blood pressure. Indeed the ACE inhibitors captopril 










increase in blood pressure ------------ retention of sodium and water
Scheme 1.1. RAS Cascade: release and physiological effects of angiotensin II
Szelke and his co-w orkers^ took the (6-13) octapeptide of human
angiotensinogen, which is itself a weak inhibitor of human renin, as a starting point 
for their work in this area and replaced the scissile amide bond between leucine and 
valine with a reduced amide link. They found that this reduced analogue was a 
potent inhibitor of human renin. The results are shown in Table 1.3.
Table 1.3. Peptide sequences and inhibitory potencies of angiotensinogen 
analogues.




The methyleneamino unit has also been used in the search for potential HTV- 
1 protease inhibitors.49 The strategy involved replacing the cleaved amide bond in a 
minimum peptide substrate with a reduced amide link. The most potent substance 
discovered in this study was Thr-Leu-Asn-Phe\jr[CH2NH]Pro-Ile-Ser, which 
displayed an IC50 of 1.4 |iM when tested for inhibition of HIV-1 protease.
Pseudopeptide analogues of the 3 opioid antagonists Tyr-Tic-Phe-Phe-OH 
and Tyr-Tic-Phe-OH, containing a reduced peptide bond between the Tic^ and Phe^ 
residues were synthesised, initially to eliminate the possibility of Tyr-Tic 
diketopiperazine formation. 50 It was found that Tyr-Ticy [ C H2NH]Phe-Phe-OH 
was almost twice as potent as a 3 antagonist than the parent peptide and ~7.5 times 
more selective for the 5-receptor than the |i-receptor than the parent, with 3-receptor 
affinity in the subnanomolar range. The pseudopeptide was also stable against 
enzymatic degradation. Tyr-Tic\j/[CH2NH]Phe-OH was found to be only slightly 
more potent as a 3 antagonist than the parent tripeptide but showed greater 3 affinity 
and a 40-fold increase in selectivity for the 3-receptor over the fi-receptor.
It has been shown that bombesin-like and gastrin-releasing peptide-like 
peptides may act as autocrine growth factors in the proliferation of some c a n c e r s . 51 
A p s e u d o n o n a p e p t i d e  bo m bes in  a n t a g o n i s t ,  (D-Tpi^,  
Leu 1 3\|/[CH2NH]Leu 1 4 ) b o m b e s i n  (6-14), was found to significantly inhibit tumour 
growth in various cancer models.
The success of the methyleneamino modification in the production of 
antagonists/enzyme inhibitors can be largely attributed to its resistance to enzymatic 
degradation. For example, in the case of the renin inhibitor,48 replacing the scissile 
Leu-Val peptide bond with a reduced peptide bond changes the geometry at this 
position. The methyleneamino moiety is isosteric with the tetrahedral transition state 
formed during amide bond hydrolysis and so the reduced analogue is bound to the 
enzyme more tightly than the substrate. Since the reduced analogue cannot be 
cleaved by renin, it acts as a potent competitive inhibitor.
One of the major characteristics of the reduced amide moiety is the 
introduction of a new base within the peptide backbone and a new ionisable site. 
This can be advantageous when dealing with highly lipophilic peptides where 
transport problems are suspected (by increasing the hydrophilicity of the peptide).
The reduced amide bond can therefore exist in different protonation states 
depending on the pH of the medium.52 At physiological pH, the reduced amide 
would be expected to exist in the protonated form
A comparison of the dimensions of the amide and the reduced amide bonds is 
given in Table 1.4.53 Dimensions are given for both the neutral and the protonated 
form of the reduced amide.
Table 1.4. Dimensions of the amide and reduced amide bonds.
Bond lengths (A) C-C<* C=0 C-N N-Ca
amide 1.52 1.23 1.34 1.45
neutral reduced amide 1.54 1.46 1.46
protonated reduced amide 1.50 1.48 1.48
One of the most significant points to consider in replacing an amide with a 
methyleneamino group is the change from sp2 to sp^ character, which increases 
backbone flexibility. This characteristic of the reduced amide link was used in the 
study of structure-activity relationships on a series of tripeptide thrombin 
inhibitors.54 Tripeptide aldehydes such as Boc-D-Phe-Pro-Arg-H exhibit potent 
direct inhibition of thrombin and Shuman et al. were interested in investigating the 
structural and conformational role of the amino acid residue in position 1. This was 
carried out by replacing the phenylalanine residue with a conformationally restricted 
amino acid such as phenylglycine to decrease the conformational flexibility of the 
peptide aldehyde. Increased conformational flexibility was achieved by replacing 
the Phe-Pro amide bond with a methyleneamino unit In this case, however, the 
increase in conformational flexibility was detrimental since the reduced analogue, 
Boc-D-Phe\|/[CH2NH]Pro-Arg-H exhibited no inhibitory activity. The authors 
postulate that one explanation might be the presence of a charged centre (the amine) 
where one did not previously exist.
The hydrogen bonding properties of the methyleneamino link differ from 
those of the native peptide bond. This is illustrated in Figure 1.2.
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Figure 1.2. Intramolecular hydrogen bonding schemes (distances in A) for (a) 
amide, (b) neutral reduced amide, (c) protonated reduced amide.
It can be deduced from Figure 1.2 that the neutral reduced amide is a weak 
proton donor and as one might expect, the protonated reduced amide is an even more 
effective proton donor than the standard amide. The nitrogen of the neutral reduced 
amide could act potentially as a hydrogen bond accepting site; a short intramolecular 
N...N distance was found in the crystal structure of BocProy [CH2NH]Leu-Gly- 
NH2.
1.8 Conformational studies on reduced peptides
The tripeptide, Pro-Leu-Gly-NH2 has some potential for the treatment of 
mental depression and Parkinsonism. Analogues of this compound containing a 
reduced peptide bond were synthesised as a means of increasing its duration of 
action by increasing its resistance to proteolysis. Conformational studies of these 
analogues were carried our by Vander Elst et alJ*$ Converging evidence from both 
theoretical and spectroscopic studies indicate that the parent tripeptide Pro-Leu-Gly- 
NH2 adopts a preferred C10 P-tum conformation in DMSO or acetonitrile solution 
and in the crystalline state. It was found that the reduced analogue HCLPro- 
Leuy[CH2NH]GlyNH2 adopted a preferred conformation in DMSO solution similar 
to that of the ’’parent". The biological activity of the reduced analogue was also very 
similar but unfortunately the reduced analogue exhibited increased toxicity levels.
- 13-
In their conformational study of modified peptides Marraud et al.53 took into 
account the effect that protonation of the reduced amide bond would have on the 
conformation of the modified peptide. These workers examined analogues of the R- 
CO-Xaa-Yaa-NHR' model dipeptide, and found that the conformational properties of 
the dipeptide modified at the C-terminal position depend on whether or not the 
reduced amide is protonated. The amine form dipeptide is flexible and gains rigidity 
upon protonation. For example, in the protonated form, the carbonyl is strongly 
hydrogen bonded to the ammonium nitrogen, producing a folded structure with a 
stabilised type II p turn.
The conformational effects of incorporating methyleneamino links in a native 
peptide have been studied in detail by Dauber-Osguthorpe et al.56 A complete 
search of the conformational space available to the modified residues was carried out 
and the effect of incorporating these residues into secondary structures was 
investigated.
The study was based on the fact that the conformational preferences of an 
isolated residue give some indication as to the likelihood of it adopting 
conformations compatible with secondary structure i.e. a residue is likely to be part 
of a secondary structure element if the required conformation corresponds to a local 
minimum of the energy surface of the isolated residue.
Representative models of the major elements of secondary structure of 
peptides and proteins were built and the modified links were incorporated in various 
locations.
The smallest peptide unit that can form a p turn is a blocked dipeptide, such 
as N-acetyl-L-alanyl-L-alanyl-N-methylamide, 2 (Figure 1.3) which was used as the 





Compound 2 contains three amide links but only the second and third links 
are candidates for reduction since reduction of the first amide link precludes 
formation of the i....i + 3 hydrogen bond. It is found that reduction of the second 
amide link, the third, or both (structures 3 - 5  respectively, Figure 1.4) results in 
relatively stable (3 turns. Excepting type I' p turns, all the modified turns are 







1.9 Synthesis of reduced peptides






P = amino protecting group 
R l and R2 = amino acid sidechains 
R3 = alkyl
Figure 1.5. A reduced dipeptide.
One of the most commonly encountered procedures is the reductive 
amination of an N-terminal protected amino aldehyde with an amino acid ester. The 
reaction is frequently carried out using solid phase methodology i.e. the 
methyleneamino link is introduced via a reductive amination reaction between an N- 
(f-butoxycarbonyl)amino aldehyde and an amine on a resin bound peptide, using 
sodium cyanoborohydride in acidified dimethylformamide solution (Scheme
1.2)49,57-61
Ri R2 O




)-ResinBocNH" '  - - -
R2 o
Rl - R3 = amino acid sidechains
Scheme 12. (i) DMF containing 1% AcOH, NaBH3CN.
There are also examples of the incorporation of methyleneamino links in 
peptides using solution phase reductive amination reactions, again between N-(r- 
butoxycarbonyl)amino aldehydes and a free amine on the peptide chain, employing 
sodium cyanoborohydride in acidified methanol or dimethylformamide.63
- 16-
Although the reductive amination reaction provides reasonable yields of 
reduced dipeptides, the procedure is not without its problems. The production of 
diastereoisomers during reductive alkylations of proline residues in peptides has 
been observed.49,60 For example, in the reaction of N-(f-butoxycarbonyl)-L- 
phenylalaninal, 7 with the resin-bound peptide ProIleSer(OBzl)OResin, 8 (Scheme
1.3),49 it was found that racemisation during aldehyde synthesis was not the sole 
reason for the production of diastereoisomers. The authors propose that the problem 
lies in the fact that proline, being a secondary amine, forms an enamine intermediate, 
9, resulting in a loss of chirality at the phenylalanine residue. Subsequent reduction 




















Scheme 13. (i) NaBH3CN.
As alluded to earlier, care must be taken during synthesis of the aldehyde 
which is to be used in the reductive amination reaction to ensure that racemisation 
does not occur.
Another popular approach to the synthesis of reduced dipeptides is 
straightforward reduction of the amide bond in the dipeptide of choice. Sodium 
bis(2-methoxyethoxy)aluminium hydride was used to reduce the amide bond in N-(t- 
butoxycarbonyl)-L-leucyl-L-leucine methyl ester.48 However, this was not a very 
desirable procedure since the methyl ester was also reduced.
- 18-
An increasing number of reduced dipeptides have been prepared by borane 
reduction of dipeptides.49,64,65 ^he borane-tetrahydrofuran complex is a very mild 
reducing agent which is commercially available in an easy to handle solution. 
However, the procedure often gives unacceptably low yields of the desired reduced 
dipeptide because it is difficult to ensure complete reduction of the amide without 
reducing the ester at the same time. At low temperatures, the starting dipeptide 
remains largely unreacted whereas at higher temperatures, concurrent ester reduction 
is a problem. These difficulties can be alleviated somewhat by the use of a large 
excess of borane at low temperature (~ - 20 °C) over a period of several hours. The 
use of a dipeptide containing a bulky ester group (e.g. butyl) also aids the 
selectivity of the reduction.
Continuing on the reduction theme, an alternative route to reduced dipeptides 
involves reduction of the corresponding endothiopeptides. Endothiopeptides can be 
prepared directly from protected dipeptides by treatment with dimeric 
phenylthionophosphine sulphide^ or Lawesson's reagent67»68 as in Scheme 1.4.
Rj O Rt O
P N H ^'^jj'' OR3 (l)or(u) > P N H '^ jj^  NV ^  OR,
O Ro S Ro
(iii)
Ri O
PNH^~^—'  NV ^  OR3
r 2
P = Z or Boc
R l and R2 = amino acid sidechains 
R3 = alkyl
Scheme 1.4. (i) dimeric phenylthiophosphine sulphide, THF (ii) Lawesson's 
reagent, PI1CH3 (iii) nickel boride.
Selective conversion of the endothiopeptide to a reduced peptide can then be 
carried out via several reductive processes, e.g. Raney nickel reduction, alkylation 
with triethyloxonium tetrafluoroborate followed by sodium borohydride reduction or 
direct reduction with nickel boride, prepared by treating nickel chloride hexahydrate 
in methanol-tetrahydrofuran with sodium borohydride. Guziec et investigated 
the relative advantages of all three procedures and concluded that the nickel boride 
reduction procedure was superior in terms of yield, reproducibility and convenience.
Methyleneamino moieties have also been incorporated into peptides via Sn2 
displacement reactions as in Scheme 1.5.69










Scheme L5. (i) Eq N, DMF.
The success of such a reaction, however, is critically dependent on the nature 
of the amino protecting group and the tosyl group has been shown to be compatible
Recently, the development of more versatile Mitsunobu reagents has made 
the alkylation of trifluoroacetamides (e.g. N-benzyltrifluoroacetamide with pKa =
the trifluoroacetamide can be hydrolysed under mildly basic conditions. This type of 
reaction has potential value in reduced peptide synthesis.
1.10 Aims
The objective was to synthesise a reduced tripeptide, 1 (Figure 1.1) in chiral 
form by building on or combining some of the known procedures for reduced 
dipeptide formation discussed above.
Initially we determined that the amino acid sidechains, R l - R3 of the 
reduced tripeptide should be kept relatively simple. Alanine was regarded as a good 
starting point since sidechain protection, or fear of sidechain interference, in any of 
the proposed synthetic routes to the target compound would not be a problem.
with this type of chemistry.70
13.6) possible.^ * This provides an excellent new route to secondary amines since
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Having thus developed the methodology for the synthesis of a fairly simple 
reduced tripeptide, it was hoped that incorporation of the sidechains of any of the 
commonly occurring amino acids into the structure would be possible.
When the synthesis of the reduced tripeptide was complete, we proposed to 
study its conformation using some of the techniques commonly employed to study 
the conformations of peptides to see how it compared to the predictions made by the 
molecular modelling study which suggested that such a structure would be likely to 
adopt a p tum.56
Many methods can be used to obtain information about the conformations of 
peptides, 1 one of the most definitive being X-ray diffraction. The only disadvantage 
is that intermolecular forces are of primary importance in the formation of the crystal 
and these can have profound effects on the conformation adopted by the peptide. 
However, the observed conformation can be counted among those accessible to the 
peptide and can possibly be related to conformations in other environments of 
interest
NMR is the most useful method of peptide conformational analysis in 
solution, yielding information about the chemical environments of nuclei, geometric 
relationships between nuclei, the distances between nuclei, the accessibility and 
hydrogen bonding of amide protons and the dynamics of nuclei. This information 
can be obtained from chemical shifts, coupling constants, nuclear Overhauser 
enhancements, exchange kinetics and sensitivity of resonance positions and 
linewidths to temperature, solvent or paramagnetic probes and relaxation times, 
respectively.
However, caution should be exercised in interpreting NMR data for peptides, 
since NMR is a "slow" spectroscopic method and so conformational 
interconversions not requiring peptide bond rotations lead to averaged NMR 
parameters.
IR spectroscopy can be used as a complementary approach to NMR and X- 
ray crystallography in determining turn conformations since amide vibrations are
- 22-
sensitive to hydrogen bonding. IR spectroscopy has the additional advantage of a 
fast time scale (10" ^  second) and so bands are seen for virtually every species 
present.
Another technique that can be used in certain cases to examine the 
conformation of a peptide is circular dichroism. CD is very sensitive to 
conformation because the arrangement of peptide bond chromophores with respect 
to each other and to asymmetric fields in the molecule varies with different 
conformations. CD also has a very fast time scale (1(H5 second). A disadvantage 
is that detailed interpretation of CD spectra for larger peptides is difficult since CD 
spectra in the peptide chromophore region are composed of broad overlapping bands 
arising from the n->n* and n-»7t* transitions of the molecule. Nevertheless, 
characteristic CD spectra are obtained for peptides containing the major secondary 
structure types. In particular, P turns yield any of three curve shapes that correlate 
with the turn type.
In addition to examining the conformation of the target reduced tripeptide, a 
study of its biological activity would also be carried out. It was anticipated that this 
could be done by incorporating the required reduced tripeptide sequence into a 
known biologically active peptide especially at points of cleavage so that resistance 
to enzymatic degradation could be investigated.
The reduced tripeptide unit, 1 (Figure 1.1) could be used as the basis for a 






We wished to investigate the possibility of reducing two amide carbonyl 
groups as a means of obtaining the desired target, 1, a reduced tripeptide (Scheme
P = N protecting group
R l - R3 = amino acid sidechains
R4  = alkyl
Scheme 2.1. (i) reducing agent
Preparation of amines by reduction of the corresponding amides is an area 
which has been extensively investigated^ and as a result, the list of reagents 
capable of reducing an amide bond is long.73 Aluminium hydrides, 
alkoxyaluminium hydrides and borane are known to be effective and, although 
sodium borohydride itself cannot reduce an amide bond, sodium borohydride used 
with certain additives e.g. titanium (IV) chloride, acetic acid or trifluoroethanol can 
successfully reduce an amide bond.
For this particular study, commercially available reducing agents with well- 
documented handling procedures were required. After some consideration, four 






hydride (1.0 M solution in hexanes), sodium bis(2-methoxyethoxy)aluminium 
hydride (65+ wt. % solution in toluene) and borane.tetrahydrofuran complex (1.0 M 
solution in tetrahydrofuran). These reagents will be refened to as LiAlH4 , DEBAL- 
H, Red-Al and BH3.THF or borane, respectively.
LiAlH4 is a very powerful reducing agent and so, perhaps not surprisingly, 
its use in the field of peptide chemistry is fairly limited. However, it has been used 
in the formation of pentaazacyclopentadecane systems, 13 by complete reduction of 
the corresponding cyclic pentapeptide precursors, 12 as in Scheme 2.2 in yields 
ranging from 23 - 11% J^
R l - Rio = amino acid sidechain or H 
Scheme 22 . (i) LLAIH4 , THF, 80 °C, 18h.
This illustrates that LLAIH4 can be used for the simultaneous reduction of 
multiple amide bonds. However, reduction of a linear tripeptide is clearly more 
complicated as amino and carboxy terminal protecting groups must now be brought 
into consideration.
Red-Al^S is also a powerful reducing agent and is known to reduce amides to 
amines as readily as LiAlH4 .74  Red-Al has been used by Szelke et al. for the 
reduction of the dipeptide N-(f-butoxycarbonyl)-L-leucyl-L-leucine methyl ester in 
their work on renin inhibitors.48 The amide and the ester were both reduced in this
bond in a compound with a much higher degree of selectivity than ULAIH4  or Red-
12 13
case.
DIBAL-H76 is a much milder reducing agent, capable of reducing the amide
Al but little is known of its ability to reduce the amide bond in a typical dipeptide.
Due to its exceptionally mild reducing capacity, there are a number of 
examples of the use of BH3 .THF in the peptide field.64,65,77,78 Selective
reduction of the amide bond in a blocked dipeptide such as 14 using borane (Scheme
2.3) has been shown to be possible by paying careful attention to reaction 
temperature and amount of borane added.164,65,77 However, there are no reports of 
the simultaneous reduction of more than one amide bond in a peptide using borane.
Rj O Rj O
P N ^ ^ N' Y ^ O R 3 ----- --— ► P N ^ ^ ' N' Y ^ O r 3
o  r 2 r 2
14 6
P = urethane protecting group 
R l - R2 = amino acid sidechains 
R3 = alkyl
Scheme 23. (i) BH3.THF, THF.
The tripeptide, methyl N-benzyloxycarbonyl-L-alanyl-L-alanyl-L-alaninate, 
18 was selected as the starting peptide for this feasibility study and was synthesised 
as shown in Scheme 2.4.
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Scheme 2.4. (i) PhCH20C0Cl, 4M NaOH, r .t, 18h (ii) AlaOMe.HCl, Et3N, 
HOBt, DCC, THF, 0 °C to r.t, 18h (iii) AlaOMe.HQ, Et3N, HOSu, EDC, CH3CN, 
r .t , 48h (iv) UOH.H2O, CH3OH, H2O, r.t, 4h.
The benzyloxycarbonyl protecting group was introduced to L-alanine under 
Schotten-Baumann conditions, giving N-benzyloxycarbonyl-L-alanine, 15 which 
was then coupled with L-alanine methyl ester to give the dipeptide ester, 16.
The coupling reaction was initially carried out with DCC under standard 
conditions .79 This gave a reasonable yield of the dipeptide, but purification of the 
product proved to be more difficult than anticipated. The problem lay in trying to 
separate the dipeptide ester, 16 from the by-product of the reaction, DCU.
In theory, it should be possible to filter off the DCU during work-up, leaving 
the peptide in solution. In practice, however, it was not as simple as this. The 
solubility properties of 16 meant that, if the DCU was filtered off, a substantial 
amount of the peptide was lost with i t  The only way around this problem was to
- 27-
avoid filtration i.e. to bring most of the DCU through the work-up procedure and 
then separate it from the dipeptide, 16 by repeated column chromatography until 
there was no further trace of DCU in the peptide. Unfortunately, this reduced yields 
of 16 considerably.
In order to overcome these problems, coupling was attempted using EDC, 
another carbodiimide coupling reagent, but one which produces a water-soluble urea 
that can be washed out during work-up.^®
The coupling reaction was repeated with EDC.8 * However, only a 
disappointing 23% yield of the dipeptide ester, 16 was obtained. This low yield was 
also attributed to the solubility properties of 16. The work-up procedure for an EDC 
coupling reaction involves washing the organic phase repeatedly with water to 
ensure complete removal of the urea by-product It was thought that the dipeptide 
16 was sufficiently soluble in water to be removed to some extent during work-up. 
Subsequently, tests on 16 showed that it has some water-solubility, enough to 
account for the poor yield.
Having discovered that the EDC coupling procedure was inefficient, we 
opted to continue with DCC coupling reactions. Although the procedure was not as 
effective as desired, reasonable yields of the dipeptide ester, 16 could be obtained in 
this way.
Ester hydrolysis with lithium hydroxide proceeded smoothly to give high 
yields of the free acid, N-benzyloxycarbonyl-L-alanyl-L-alanine, 17 which was then 
coupled with L-alanine methyl ester, using DCC, to give the desired tripeptide, 18 in 
58% yield.
The next step was reduction of the tripeptide 18 which was to be carried out 
using the four reducing agents discussed above: LiAlH4 , DIBAL-H, Red-Al and 










R = Z or H
Scheme 2.5. (i) LiAlH4 , THF (ii) DIBAL-H, THF (iii) Red-Al, THF (iv) 
BH3 .THF, THF.
As indicated in Scheme 2.5, the reduction was not expected to be selective 
except, perhaps, in the case of borane. However, this was not a major concern. The 
main objective of this exercise was to reduce the two amide bonds in the tripeptide 
18, thus forming the backbone of the reduced tripeptide. The amino and carboxy 
terminals could be modified by further studies.
In each case, tripeptide 18 was dissolved in THF and the reducing agent was 
added one equivalent at a time at -78 °C. The reaction mixture was then closely 
monitored. No reaction occurred on allowing the reaction mixture to warm to room 
temperature, or on refluxing, when only one equivalent of reducing agent had been 
added. The same results were obtained in each case upon addition of a second 
equivalent of reducing agent Reaction only began to take place upon heating when 
three or more equivalents of the reducing agent had been added to the mixture.
At this point reaction was quenched and an attempt made to separate the 
components of the respective mixtures by column chromatography.
- 29-
The results of this study were disappointing since none of the desired reduced 
tripeptide was ever isolated, despite the fact that each reaction mixture was 
apparently composed of several compounds. It is assumed that the first two 
equivalents of the reducing agent merely bind to the tripeptide 18 and any reducing 
agent added thereafter results in cleavage of the tripeptide, particularly at elevated 
temperatures.
It was clear that none of the desired target compound could be obtained 
through this direct line of attack, suggesting that a more indirect approach to the 
reduced tripeptide via amide reduction might be the answer.
There are examples in the literature of formation of a reduced dipeptide by 
selective reduction of the amide bond in a blocked dipeptide using BH3.THF. 
Roeske et al. reduced N-(f-butoxycarbonyl)-L-glycyl-L-leucine methyl ester, 19 as 
in Scheme 2.6, giving the desired reduced dipeptide, 20 in 22% yield. 64
Scheme 2.6. (i) BH3.THF, THF, -20 °C, 4h.
The best conditions to minimise ester reduction were 2 mol BH3 at -20 °C 
for ~4h. However, some alcohol and 41% unreacted starting material were isolated 
from the reaction mixture.
The conditions used by Oyamada and Ueki were more useful, selectively 
reducing N-benzyloxycarbonyl-L-phenylalanyl-L-leucine methyl ester, 21 to the 
reduced dipeptide ester 22 in 64% yield (Scheme 2.7).65 These authors used 10 
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Scheme 2.7. (i) BH3.THF, THF, 0 °C, lOh.
We decided to investigate the possibility of reducing the amide bond 
selectively in N-benzyloxycarbonyl-L-alanyl-L-alanine methyl ester, 16 according to 
the method of Oyamada and Ueki.65 if this left the ester function intact as in 23, it 
would then be possible to build on the carboxy terminal (Scheme 2.8).
OMe Q  Z N H ^ ^ N>Y ^ 0Me 
O 1 5
16 23
(ii) , 1 £<* N (iii)
ZNH‘X^ —" OMe
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Scheme 2.8. (i) BH3.THF, THF, -78 °C to 0 °C, 8h (ii) (Boc)20, NaOH, H2O, r.t.
(iii) Li0H.H20, CH3OH, H2O (iv) AlaOMe.HCl, Et3N, HOBt, DCC, THF (v) 1M 
HC1,1,4-dioxane.
Protection of the new amine function on 23 would be necessary to avoid 
unwanted side reactions in later steps. A f-butoxycarbonyl protecting group could be 
introduced to 23 using di-f-butyl dicarbonate under Schotten-Baumann 
conditions.83>84 This derivative would be stable to the ester hydrolysis step, giving
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the free acid 25, and also to the conditions required to couple 25 with L-alanine 
methyl ester.
Compound 26 contains a reduced amide bond and an amide bond. Assuming 
that the first step in the pathway proceeded as planned, the same conditions could 
now be used to reduce the amide bond in 26.
The work-up procedure for a borane reduction reaction involves the use of 
hydrochloric acid for a short time and so the f-butoxycarbonyl protecting group 
might not be able to withstand this step. However, at this stage in the synthesis it 
would be of no consequence, as loss of the f-butoxycarbonyl protecting group would 
merely render step (v) unnecessary.
Reduction of N-benzyloxycarbonyl-L-alanyl-L-alanine methyl ester, 16 was 
carried out as in Scheme 2.8, using 10 equivalents of BH3.THF.65 The reaction was 
quenched after 8 hours, although there was still some starting material present 
because it was observed that a more polar compond than the reduced dipeptide, 
which was assumed to be the alcohol, was forming. The result of this reaction was 
not encouraging; only 2% of the desired compound, 23 was isolated, along with 12% 
unreacted starting material. Peptide and reduced peptide alcohols were assumed to 
be present in the reaction mixture but their existence was not proven.
Having obtained such a low yield for the first step of the proposed pathway, 
it seemed futile to carry on. It was obvious that it would be difficult to optimise the 
yield for this selective amide reduction without changing the peptide to one with an 
ester stable to these reductive conditions such as f-butyL
Since earlier work had shown the benzyloxycarbonyl group to be stable to 
LiAlH4  at moderate temperatures, one option was to reduce the dipeptide 16 using 
LiAlH4 , thus forming the reduced peptide alcohol, 29 as in Scheme 2.9. It was 
thought that this reaction might proceed in reasonable yield, since, given that 
selectivity was no longer a requirement, the reaction would be allowed to go to 
completion. If this was found to be the case then subsequent oxidation of the alcohol 
and extension at the carboxy terminal, as proposed earlier, would be feasible.
- 33-
V r1' (i)-X-ZNH > r  OMe ZNH V  OH
O
16 29 
Scheme 2.9. (i) LiAlHLj., THF, 0 °C to r.t., 2h.
Accordingly, N-benzyloxycarbonyl-L-alanyl-L-alanine methyl ester, 16 was 
dissolved in THF and the solution added slowly to LiAlH4 (3 equivalents) at 0 °C. 
The reaction was quenched, when, after 2 hours stirring at room temperature, all the 
starting material appeared to have been used up. However, the product isolated from 
this reaction was not the reduced peptide alcohol, 29 but merely the peptide alcohol, 
30 (Figure 2.1).




Clearly, ester and amide reduction could not be effected in one pot and so 
alcohol 30 was subjected to a further reduction reaction (Scheme 2.10).
"VS (i)-X-ZNH Y  OH ~  ZNH‘
O
30 29
Scheme 2.10. (i) LiAlfLj., THF, 0 °C to r.t, 54h.
Peptide alcohol 30 was dissolved in THF and 2 equivalents of LiAlH4 were 
added to the solution at 0 °C. After stirring for 6 hours at room temperature, no 
reaction had taken place. It was considered unwise to heat the reaction mixture, in 
view of earlier experiences, in case this would lead to cleavage of the starting 
material or loss of the benzyloxycarbonyl protecting group and so another equivalent
- 34-
of LLAIH4  was added to the reaction mixture. Stirring was continued for a further 48 
hours and the reaction was then quenched. Surprisingly, only the unreacted starting 
material, 30 was isolated from the reaction mixture.
It was thought impossible that the peptide alcohol 30 could withstand so 
much LiAlH4 , although, with hindsight, perhaps complexation of LiAlH4  with the 
free hydroxyl group was a much greater factor in the failure of the reaction than 
anticipated. Perhaps if the hydroxyl group been protected e . g .  as a t- 
butyldiphenylsilyl ether^5,86 which is stable to L iA lH ^^ and can be easily
removed by treatment with fluoride ion, before further reduction was attempted, the 
reaction would have been successful.
The peptide reduction work was concluded at this point despite the fact that 
there were a number of avenues left to explore including reduction of 
endothiopeptides. However, preliminary results had not been encouraging and there 





The Mitsunobu reaction, using the diethyl azodicarboxylate - 
triphenylphosphine redox system, is a versatile method for the condensation of 
alcohols (ROH) and various nucleophiles (or acids, HA) to give the products RA and 
is widely used in organic synthesis^ (Scheme 3.1).
ROH + HA 
Scheme 3.1. (i) DEAD, Ph3P.
(i) RA
The generally accepted pathway for the reaction is outlined in Scheme 3.2.
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Scheme 32.  (i)Ph3P (ii)ROH (iii)HA.
(iii)
EtOOC- N - N -  COOEt + RA + Ph3P = 0  
I I J
- 36-
The limitation of the reaction is that the acidic hydrogen in HA has to have a 
pKa of less than 11 for the reaction to proceed satisfactorily.
Recently new redox systems have been introduced which can be applied to 
the reaction of HA of pKa greater than 11.71,88 These new approaches arose from 
the following considerations:^
1. Ways to increase the nucleophilicity of the phosphine in the formation of 32 and 
to localise the positive charge on phosphorus in intermediates 32 and 34, thereby 
assisting nucleophilic attack of RO" or A” respectively. In both cases, it was thought 
that tributylphosphine would be a good alternative to triphenylphosphine.
2. Ways to localise the negative charge at the nitrogen atom, increasing its basicity 
in the intermediate 33. This could be done by the use of reagents such as 1,1- 
(azodicarbonyl)dipiperidine (ADDP), 36, N,N,Nf,N'-tetramethylazodicarboxamide 
(TMAD), 37 or N,N,N,Nf-tetraisopropylazodicarboxamide (TIPA), 38 in place of 
diethyl azodicarboxylate, 31 (Figure 3.1).
EtOOC N -N  COOEt ^  \ p C — N = N —  COl/  ^
3631
V -
NOC— N =N —  CON 
Figure 3.1.
Tsunoda et al. investigated the reaction of N-benzyltrifluoroacetainide, 39, 
which has a pKa of 13.6, with various alcohols using these four Mitsunobu reagents. 
The results are presented in Table 3.1.71
\ /




Table 3.1. Mitsunobu alkylation with some azo compounds (% Yield of RA).
(i)ROH ------------------   RA
(i) HA (1.5 eq.), azo compound (1.5 eq.), phosphine (1.5 eq.), solvent, r.L, 24h.
HA
F3CCONH/ V s Ph
39
ROH D n A t m OO
benzyl
alcohol
3 77 53 86
n-butanol -(b) 30 48 83
crotyl alcohol _ 70 56 78
(a) D: DEAD-PI13P in THF 
TI: TIPA-BU3P in PhH 
A: ADDP-BU3P in PhH 
TM: TMAD-Bu3PinPhH
(b) - no experimental result
Table 3.1 shows that the azodicarboxamide (amide reagents) activate the 
reactions of N-benzyltrifluoroacetamide more efficiently than traditional DEAD. 
TMAD, having the smallest alkyl groups on the amide nitrogens gives the best 
overall results (enabling the HA of pKa ~ 13.5 to be alkylated in satisfactory yields).
The efficient alkylation of N-benzyltrifluoroacetamide using TMAD 
provides an excellent route to secondary amines, since the trifluoroacetamide 
product from the Mitsunobu alkylation can be easily hydrolysed under mildly basic 
conditions.89,90 This is a great improvement on similar work done previously in 
which N-methyl p-toluenesulphonamides and N-(f-butoxycarbonyl) p-  
toluenesulphonamides were coupled with a variety of alcohols to afford
- 38-
sulphonamide-protected amines. 91 In order to obtain the free amine in this case, 
deprotection with sodium naphthalenide^ 0r sodium in liquid am m onia^ was 
required.
This led us to consider whether the Mitsunobu reaction could be used in the 
synthesis of a reduced dipeptide, 45 or even a reduced tripeptide, 40. A 
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R = amino acid sidechain.
P = amino protecting group.
Scheme 3.5. (i) TMAD, BU3P, PhCH3 (ii) selective reduction.
O
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In alcohol 42, a protecting group was required which would not interfere at 
all in the reaction. A phthalimide group was selected since it would completely 
protect the nitrogen and delocalise the lone pair. N-Phthaloyl-L-phenylalaninol, 49 
was synthesised as shown in Scheme 3.6.
CH2Ph






Scheme 3.6. (i) LLBH4 in THF, TMSC1, r.t, 18h (ii) phthalic anhydride, 140 °C, 
2h.
Attempts were made to reduce L-phenylalanine using sodium b o r o h y d r i d e ^ 4  
and lithium borohydride in T H F . 9 5  The lithium borohydride reduction was found to 
be preferable since work up was more straightforward and higher yields of L- 
phenylalaninol, 48 were obtained.
Nucleophile 47 could be easily prepared by treating an amino acid methyl 
e s te r  w ith triflu o ro ace tic  anhydride. (S )-(-)-M eth y l N- 
(trifluoroacetyl)phenylalaninate, 50,96 was prepared from L-phenylalanine methyl 
ester hydrochloride (Scheme 3.7).
CH>Ph CH2Ph
F jC C O N H '^Y  0Me 
50 °





It was thought unwise to use the two novel substrates, 49 and 50 in this type 
of Mitsunobu alkylation without first investigating their reactivity. Since the success 
of the reaction under the proposed conditions depended on the nucleophile (or acid, 
HA) having a pKa of approximately 13.5 or less, we decided to test the reactivity of 
our novel nucleophile, 50 with an alcohol which had previously been used in this 
type of reaction. The trifluoroacetamide, 50 was therefore alkylated with benzyl 
alcohol as in Scheme 3.8.
CH2Ph
Scheme 3.8. (i) TMAD, Bu3P, PI1CH3, 0 °C to r.t, 24h.
Product 51 was isolated from the reaction mixture in a disappointing 10% 
yield. Nevertheless, this illustrated that nucleophile 50 could be used in reactions of 
this type and so an attempt was made to alkylate 50 with N-phthaloyl-L- 












Scheme 3.9. (i) TMAD, B113P, PhCH3, 0 °C to r.t., 24h.
None of the desired product, 52 was isolated from the reaction. Since the 
nucleophile 50 had already been used in a successful, albeit low-yielding, reaction of 
this type, it was concluded that the reactivity problem lay with the alcohol, 49. In 
order to investigate whether the steric bulk of the phenylalanine sidechain in alcohol 
49 was having an adverse effect on the reaction, an attempt was made to alkylate the 
trifluoroacetamide, 50 with N-(2-hydroxyethyl)phthalimide, 53 under the same 
conditions (Scheme 3.10).
+ F3 CCONH
Scheme 3.10. (i) TMAD, Bu3P, H1CH3, 0 °C to r.t, 24h (ii) 110 °C, 7h.
The desired product 54 was not isolated from the reaction mixture, 
suggesting that the problem did not lie with the bulkiness of the sidechain in 49.
Attention was redirected to the reaction shown in Scheme 3.9. The 
components of the reaction mixture had been separated by column chromatography 
and, although appreciable amounts of starting materials 49 and 50 were recovered, it 
was clear that the problem could not be wholly attributed to the fact that the starting 
materials simply did not react under these conditions since tributylphosphine oxide 
and dihydro-TMAD, 55 (Figure 3.2) were also isolated from the reaction mixture. 
These products could not be formed without the participation of alcohol 49.
These authors found that the presence of a phthaloyl protecting group led to the 
formation of significant amounts of oxazoloisoindoles, intramolecular cyclisation 
by-products, when the p-hydroxy group was converted to a good leaving group. For 
example, in the reaction of triflate 56 with glycine /-butyl ester 57 (Scheme 3.11), 
the desired secondary amine 58 was formed in 60% yield, while oxazoloisoindole 
by-product 59 was formed in 26% yield. The oxazoloisoindole 59 is formed by an 
intramolecular cyclisation, producing an intermediate iminium ion, 60, which can 
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Scheme 3.12. (i) Glycine f-butyl ester, DIEA, DMF, 0 °C, 36h.
Applying this mechanism to the reaction of methyl N-trifluoroacetyl-L- 
phenylalaninate, 50, with N-phthaloyl-L-phenylalaninol, 49 (reagents and conditions 
are shown in Scheme 3.9), the equivalent of Ph3P+-0-R, 34 would be 61 (Figure 
3.3).
-45-
O -P B u
Figure 3.3.
Since the P-hydroxy group has been converted into a good leaving group it is 
possible that 61 could react in a manner similar to that observed by Rapoport et 
al.?7  forming the cyclic iminium ion 62 (Scheme 3.13). The presence of 62 in the 
reaction has not been proven. However, its existence would account for the 
formation of the tributylphosphine oxide and dihydro-TMAD which were isolated 
from the reaction mixture. Since no products resulting from the further reaction of 
the iminium ion, 62 were isolated, it is presumed that the ion decomposes or is 
hydrolysed back to the starting alcohol, N-phthaloyl-L-phenylalaninol under the 
reaction conditions, or during work-up.
62
Scheme 3.13.
In parallel to attempts to alkylate methyl N-trifluoroacetyl-L-phenylalaninate, 
50 under Mitsunobu conditions, work was also carried out on a more conventional 
alkylation of 50 with an alkyl h a l i d e . 9 8
N-Phthaloyl-L-phenylalaninol, 49 was converted to its bromo derivative as in 
Scheme 3.14.99
-46-
O 49 O 63
Br
Scheme 3.14. (i) CBr4 , PI13P, CH2CI2, 0 °C to r.t, 4h.
An attempt was then made to alkylate methyl N-trifluoroacetyl-L- 
phenylalaninate, 50 using bromide 63 (Scheme 3.15).
Scheme 3.15. (i) K2CO3, DMF, r .t, 24h (ii) 153 °C, 3h.
The mixture was stirred at room temperature for 24 hours and, since no 
reaction had taken place, was then heated at reflux for 3 hours. After this time, it 
was evident that some reaction had occurred. The reaction mixture was now 
composed of several different components, including some unreacted starting 
materials. These components were separated as far as possible by column 
chromatography.
No compound corresponding to the desired product 52 was isolated. Indeed, 
the only compounds isolated in characterisable quantities were the unreacted starting 
materials 63 and 50. However, it had been evident on monitoring the reaction that 
some reaction had taken place when the mixture was heated at reflux. This 






Although bromide 63 is stable on its own, the (3-hydroxy group has been 
converted into a good leaving group and it is conceivable that, under the reaction 
conditions, it is converted to a cyclic iminium ion as in Scheme 3.16.
Scheme 3.16.
As before, the existence of the iminium ion 62 has not been proven. 
However, assuming that it was formed and subsequently decomposed under the 
reaction or work-up conditions, it provides an explanation for the observations made 
on monitoring the reaction i.e. despite the fact that some reaction apparently took 
place, none of the desired product 52 was formed. Some of the starting materials 
were isolated and the presence of other compounds, which could be species resulting 
from the decomposition of the iminium ion 62, were evident from TLC. 
Unfortunately they were not present in large enough quantities to allow their 
isolation and characterisation.
In conclusion, most of the problems encountered in this work were 
apparently due to the phthalimide protecting group. While the next step would be to 
repeat some of this work using an amino alcohol with a different amino protecting 
group e.g. a tetramethyldisilylazacyclopentane or STABASE adduct,^® which 
would also completely protect the nitrogen, reductive amination work, which was 
being carried out at the same time, was now showing more promise and so effort was 






Reductive amination of an N-protected amino acid aldehyde with a (peptide) 
amine in the presence of sodium cyanoborohydride is a commonly used method for 
the synthesis of reduced peptides. In many cases, the reaction is carried out on solid 
ph ase^ ,57,59-61 \ e between a protected aldehyde and an amino group on a resin 
bound peptide. With the emergence of combinatorial synthesis by solid phase 
methods as a powerful tool for drug discovery, the reductive amination of support- 
bound aldehydes and ketones is now being used for library generation e.g. in the 
synthesis of 4-aminoproline analogues*^ and piperazinediones.^ However, there 
are many examples where reductive amination has been used in solution phase 
reduced peptide synthesis.48,62,63,102,103
We decided to apply the solution phase reductive amination procedure to the 
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P = amino protecting group 
R l - R3 = amino acid sidechains 
R4  = alkyl
Scheme 4.1. (i) NaBH(OAc)3, THF (ii) N-deprotection.
The first point to consider was the synthesis of the aldehyde. There are many 
ways to synthesise an aldehyde 104 but the method of Fehrentz and C a s t r o  105 was 
selected since it provides a convenient preparation of N-(/-butoxycarbonyl)amino 
aldehydes from the corresponding acids in high yield via reduction of an N- 
methoxy-N-methylamide. This method is based on earlier work by Nahm and
-50-
W einrebl06 which showed that N-methoxy-N-methylamides could be easily 
reduced to aldehydes using lithium aluminium hydride or diisobutyl aluminium 
hydride.










Scheme 4.2. (i) N,0-dimethylhydroxylamine hydrochloride, EDC, Et3N, CH2CI2 , 
r .t, 18h (ii) LiAlH4, THF, 0 °C to r .t, 20 min then KHSO4  (aq).
Coupling of N-(r-butoxycarbonyl)-L-alanine, 6 4 and N ,0 - 
dimethylhydroxylamine hydrochloride was initially attempted with DCC and 
triethylamine in THF.79 This reaction was low-yielding and the product N- 
methoxy-N-methylamide, 65 was difficult to separate from the by-product of the 
reaction, DCU. These problems were alleviated when EDC was used as the 
coupling reagent instead. ^  Higher yields were obtained and since EDC produces 
a water-soluble urea which can be washed out during work-up, no further 
purification of 65 was required.
Reduction of the N-methoxy-N-methylamide 65 with LiAlH4  followed by 
aqueous work-up gave N-(f-butoxycarbonyl)-L-alaninal 66 in high yield, with an 
optical purity comparable to that obtained by Fehrentz and Castro. 105 The aldehyde 
66 was then used in reductive amination reactions without further purification. We 
found that storage of the aldehyde was detrimental, leading to its decomposition and
-51-
racemisation. Since the N-methoxy-N-methylamide, 65 is very stable, it can be 
prepared in large quantities, then stored and reduced to the aldehyde as required.
Reductive amination of aldehyde 66 was carried out using L-alanine methyl 
ester and L-phenylalanine methyl ester (Scheme 4.3).
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a :R  = CH3 
b :R  = CH2Ph
Scheme 4.3. (i) Et3N, THF, AcOH, powdered 3A molecular sieves, r .t ,  lh  then 
NaBH(OAc)3, r.L 18h (ii) 1M HC1,1,4-dioxane, r.t, 2h.
Sodium cyanoborohydride108,109 [s traditionally used in reactions of this 
type but in this case the less toxic sodium t r i a c e t o x y b o r o h y r i d e ^ , 1 1 0 , l l l  was used. 
In addition to being less toxic, its use also eliminates the risk of any residual cyanide 
in the product or in the work-up waste stream.
The reductive amination reaction proceeded in reasonable yield to give 68a. 
Higher yields of 68b were obtained. This difference is probably due to the amino
-52-
acid esters themselves rather than the reductive amination reaction. A frequently
ester with itself. Since it has a less bulky sidechain, alanine methyl ester is more 
prone to this reaction than phenylalanine methyl ester.
Figure 4.1. A diketopiperazine.
N-(f-Butoxycarbonyl)-deprotection of 68a,b with hydrochloric acid afforded 
good yields of the N-terminal deprotected reduced dipeptides 69a,b (Scheme 4.3), 
which were obtained as di-hydrochloride salts. The next step was to attempt the 
reductive amination of N-(f-butoxycarbonyl)-L-alaninal, 66 with 69a (Scheme 4.4).
Scheme 4.4. (i) Et3N, THF, AcOH, powdered 3 A molecular sieves, r.t., 1.5h then 
NaBH(OAc)3, r.t., 4h.
observed side reaction of amino acid esters is the formation of diketopiperazines 112- 











In 69a there are two amino sites at which reaction could occur. However, it 
was hoped that some selectivity might be induced in the reaction by the fact that the 
terminal primary amine site is less hindered than the secondary amine site. 
Unfortunately, the reaction did not proceed cleanly, making isolation and 
purification of the products difficult. A very small amount of the desired reduced 
tripeptide, 71, equivalent to ~2% yield, was isolated. Even this small sample was 
not pure enough for full characterisation but it was identified by *H NMR and mass 
spectral analysis. The NMR is shown in Figure 4.2 and clearly contains three 
methyl doublets at d 1.03, 1.15 and 1.30, corresponding to the three alanine 
sidechains present in the reduced tripeptide, 71.
-54-
Figure 4 2

























Since the secondary amine in unprotected form may be a cause of side 
reactions, the protection of the newly formed secondary amine component in the 
reduced dipeptide 69 was thought necessary before further reductive amination with 
66 . It was thought that a benzyloxycarbonyl protecting group would be most 
desirable in this position since it would be stable to the N-(f-butoxycarbonyl) 
deprotection conditions required and could easily be removed at the end of the 
proposed pathway by hydrogenation, without interfering with any of the other 
functionality present in the target compound.
Since reduced dipeptide 68b could be prepared in higher yield than 68a, it 
was used in the remainder of this work. Benzyloxycarbonyl protection of 68b was 
carried out under phase transfer conditions (Scheme 4.5).
Scheme 4.5. (i) PI1CH2OCOCI, 10% NaOH, CH2CI2 , benzyl triethylammonium 
chloride, 0 °C to r.t, 2.5h (ii) 1M HC1,1,4-dioxane, r.t, 2h.
N-(f-Butoxycarbonyl)-deprotection of the orthogonally protected reduced 
dipeptide 72 was carried out as before, yielding 73. Interestingly, compounds 72 and 
73 exist as rotamers, presumably due to restricted rotation around the C-N bonds 
now that the secondary amine function has been protected with a bulky 
benzyloxycarbonyl group. This is evident from the NMR of compound 72 











there are two sets of peaks for every group. On heating to 70 °C (Figure 4.4), these 
merge, leaving only the one set of peaks.
Figure 4.3





NMR of compound 72 at 70 °C.
BocNH OMe
-59-
The next step was a reductive amination reaction between N-(r- 
butoxycarbonyl)-L-alaninal, 66 and the reduced dipeptide, 73 (Scheme 4.6).
I WJL n X










Scheme 4.6. (i) Et3N, THF, AcOH, powdered 3 A molecular sieves, r .t, 1.5h then 
NaBH(OAc)3, r . t ,  18h.
The reaction proceeded cleanly but the desired product 74 was not isolated. 
The major product of the reaction was the cyclic compound l-benzyloxycarbonyl-2- 
benzyl-3-oxo-5-methyl-piperazine, 75 (Figure 4.5) formed from 73 by a 6-exo-trig 
cyclisation.
Figure 4.5.
It was initially thought that cyclisation of 73 occurred under the conditions 
required for the reductive amination reaction, since the compound seemed to be 
stable, although rather hygroscopic, on its own. Studies were carried out to discover 
why cyclisation to 75 was occurring. The reductive amination reaction was repeated 




slowly in solvent at room temperature. On addition of base, however, the cyclisation 
is virtually spontaneous.
With hindsight, this cyclisation could have been avoided if a bulkier ester 
group e.g. r-butyl, had been used instead of a methyl ester. However, at this stage, 
repeating the entire synthetic pathway with different protecting groups would be too 
time consuming and it was felt that the time could be better spent in exploring some 
alternative methods of synthesising the reduced tripeptide.
In conclusion, we found reductive amination of an N-(f-butoxycarbonyl)- 
protected amino aldehyde with an amino acid ester to be a very good method for the 
preparation of a reduced dipeptide. Unfortunately, the procedure could not be 




Preparation of reduced peptides via nucleophilic displacement of a good 
leaving group by an amino acid ester (Scheme 5.1) is very attractive, in theory. 
However, in practice, such reactions can be problematic, mainly due to undesirable 
side reactions involving the amine protecting groups.70»97 We have found this in 
previous work, discussed in Chapter 3, when displacement of bromide ion by an N- 
trifluoroacetyl amino acid ester was hindered by interference of the phthalimide 
group.
Ri R2








P = amino protecting group 
X = good leaving group 
R l, R2 = amino acid sidechains 
R3 = alkyl
Scheme 5.1. (i) basic conditions.
In a recent paper detailing problems encountered in reactions of this type,70 
the authors report that the reaction is successful when the amino protecting group, P 
and the leaving group, X are both tosyl groups. A tosyl group, requiring sodium 
naphthalenide92 or sodium in liquid ammonia^3 for its removal, would never be the 
protecting group of choice. However, we decided to investigate this possibility 
further.
-62-
A stock of L-phenylalaninol, 48, prepared by lithium borohydride reduction 
of L-phenylalanine^S for earlier work, was available and this was converted into N, 
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Scheme 5.2. (i) LiBH4  in THF, TMSC1, r.L, 18h (ii) TsCl, py, CH2CI2 , 0 °C to r.L, 
2h.
The tosylate, 76 was then reacted with L-alanine methyl ester under basic 
conditions in order to form the reduced dipeptide, 77 (Scheme 5.3).
TsNH
CH2Ph 






CH2Ph 0  PhH2C. V
= Ts
77 78
Scheme S3 , (i) DIEA, CH2CI2, r.L, 18h.
The reduced dipeptide, 77 was formed in only a disappointing 13% yield. 
The major product of the reaction was the aziridine, 78. This prompted us to 
investigate whether the aziridine was an intermediate in this reaction. The aziridine, 




Scheme 5.4. (i) DIEA, CH2CI2 , r .t, 18h.
The possibility of an aziridine intermediate in a reaction of this type was 
suggested by Ondetti et al$9  An aziridine intermediate was also proposed by 
Atherton and Meienhofer in their synthesis of a ,  p-diaminobutyric acid via 
















Scheme 5JS. (i) NH3, CH3OH, r.t, 48h then 6N HC1, reflux, 3h (ii) Na, liq. NH3 , 
-33 °C, 20 min.
Aziridines are very useful synthetic intermediates which require activation by 
an electron withdrawing group on the ring nitrogen for ring-opening at C2 - The 
tosyl group is the most commonly used. Due to their synthetic utility, there are 
many examples of aziridine ring-opening reactions in the literature. Aziridine 78 has 
been used in the synthesis of (R)-ethyl (5-benzyl-2-oxo-l-tosyl)pyrrolidine-3- 
carboxylate,H6 aiso for the alkylation of dianions of glyoxylic acid derivatives, 
directed at a synthesis of the microbial metabolites, cytochalasins A, B and F.H7
-64-
Aziridines have been ring-opened with piperidine 1 ^  and tributyltin 
radicals 119 and with dimethyloxosulphonium methylide to form the corresponding 
azetidines.120 The synthesis of Na , NP-alkylated diaminopropionic acid analogues 
and /ra/w-3-(2-aminocycloalkyl)indoles, conformationally constrained serotonin 
analogues, has also been realised through aziridine ring-opening reactions 1^1 and 
recently molecular sieves have been found to enhance the regioselectivity of the 
imidochromium complex-catalysed azidolysis of N-tosyl aziridines. 1 ^
The puzzle in this case was why the aziridine, 78 did not go on and react with 
the L-alanine methyl ester to a greater degree than was observed.
The problem could lie with the use of L-alanine methyl ester. Reaction of 
amino acid esters with themselves to form diketopiperazinesl 12,113,114 js common 
and is a greater problem with those amino acid esters which have neither bulky 
sidechains nor bulky ester groups. It is possible that the L-alanine methyl ester 
could be reacting with itself under the basic reaction conditions to form its 
diketopiperazine, 70 (Scheme 5.6). This would clearly preclude further reaction of 
the aziridine, if indeed, it was the reaction intermediate.
c r a 3N+^ | f ° Me '  L  A .




Scheme 5.6. (i) DIE A, CH2CI2, r .t, 18h.
However, since none of the diketopiperazine was isolated from the reaction 
mixture, we could not be certain that the reactivity problem lay in our use of L- 
alanine methyl ester.
Two courses of action, which might elucidate the matter were selected:
1. L-alanine f-butyl ester would be used in place of L-alanine methyl ester,
2. by way of comparison, aziridine 78 would be deliberately synthesised and 
subjected to further reaction.
N, O-Di-tosyl-L-phenylalaninol, 76 was converted into aziridine, 78 as in 
Scheme 5.7. The aziridine was obtained in 41% yield and its data was found to be 
consistent with that of the earlier batch of aziridine and also with the published 
data.H6,117 js interesting to note from the NMR [Figures 5.1 and 5.2 (an 
expansion)] that there is zero coupling between the two geminal protons on the 
aziridine ring. Both give doublets (d 2.17 and d 2.71).
CH2Ph PhH2C




Scheme 5.7. (i) EqN, CH2CI2 , r.t, 72h.
Figure 5.1
NMR of aziridine 78.
-67-
Figure 53
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Two parallel reactions were then set up in order to prove the intermediacy of 
the aziridine, 78 in the tosylate displacement reaction (Scheme 5.8). This time the 
reaction conditions were modified somewhat to agree with the original procedure.69








Scheme 5.8. (i) AlaOtBu.HCl, Eq N, DMF, 80 °C, 18h.
In each case, the reduced dipeptide 79 was obtained in reasonable yield with 
retention of stereochemistry at the carbon bearing the phenylalanine sidechain, thus 
proving that reaction can proceed via the aziridine 78. The use of L-alanine /-butyl 
ester in place of the methyl ester also produced a marked improvement in the yield 
of the desired dipeptide, lending weight to the argument for the formation of the 
diketopiperazine in the case of the methyl ester.
Having successfully synthesised the reduced dipeptide 79, the aim was to 




R \ = amino acid sidechain 
R.2 = alkyl 
Figure 5.3.
This could best be done by building on the carboxy terminal of the reduced 
dipeptide, 79 since removal of the /-butyl ester would be much easier than removal 
of the tosyl protecting group92,93 at the amino terminal.
However, before any further work could be carried out on 79, it was 
necessary to protect the newly formed secondary amine function. In order to form 
an orthogonally protected compound, an attempt was made to put a 
benzyloxycarbonyl protecting group on the secondary amine under phase transfer 
conditions (Scheme 5.9).
CH2Ph O CH2Ph OJCa Jl , g ■ JC O l,TsNH OlBu X TsNH OBu
79 81
Scheme 5.9. (i) PhCH20C0G, 10% NaOH, CH2CI2 , benzyltriethylammonium 
chloride, 0 °C to r.t, 8h.
Following the failure of this reaction, the benzyloxycarbonyl protection was 
attempted again, this time under more forcing conditions (Scheme 5.10).
CH2Ph O CH2Ph O
I B 11 ® 1 6 1L
T sN H ^ ^ —" V '^ O 'B i i  *  -  T s N H ^ ^ ^  >sr o tBu
79 81
Scheme 5.10. (i) PhO^OCOCl, Et3N, CH2CI2, 40 °C, 2h.
This reaction was also unsuccessful, suggesting that the failure to get a 
benzyloxycarbonyl protecting group on the secondary amine function of reduced 
dipeptide 79 could be attributed to the steric bulk of the phenylalanine sidechain, 
preventing the approach of the benzylchloroformate, which is also very bulky, to the 
amine.
There were two possible ways to circumvent this problem:
1. use a smaller protecting group for the secondary amine;
-70-
2. synthesise an analogue of reduced peptide 79 e.g. by replacing the phenylalanine 
sidechain with an alanine one, thus allowing the introduction of the 
benzyloxycarbonyl protecting group.
By way of comparison, both possibilities were explored.
Reduced dipeptide 79 was protected with an N-acetyl group as in Scheme 
5.11. Due to the rather harsh deprotection conditions required, refluxing 2M 
hydrochloric acid 123 or treatment with 85% hydrazine hydrate at 70°C,124 ^  n_ 
acetyl function would clearly never be the first choice of protecting group. 
However, it is relatively small, as desired and, in this case, would allow the 
continuation of the proposed pathway to the reduced tripeptide 80, as a feasibility 
study, even if it meant leaving it in protected form at the end.
Scheme 5.11. (i) (CH3CO)2 0 , py, r.t., 3h.
In parallel, work was carried out towards the synthesis of a different reduced 










Scheme 5.12. (i) TsCl, py. CH2CI2 . 0 °C to r.t., 3h (ii) AlaOtBu.HCl, EgN, DMF, 
r.t., 18h.
L-Alaninol was converted to tosylate 84 which was then reacted with L- 
alanine /-butyl ester, giving the reduced dipeptide 85 in 36% yield. In order to prove 
that this displacement reaction also proceeded via an aziridine intermediate, aziridine 
86120 was synthesised and then reacted with L-alanine /-butyl ester as in Scheme 
5.13. The desired reduced dipeptide 85 was obtained in 31% yield.
Scheme 5.13. (i) EqN, CH2CI2 , r .t, 18h (ii) AlaO^u.HCl, Et3N, DMF, r.t, 48h.
The question to be addressed now was whether or not a benzyloxycarbonyl 
protecting group could be introduced to the secondary amine in the reduced 







alanine sidechain. Benzyloxycarbonyl protection of the amine in 85 was carried out 




Scheme 5.14. (i) PhOfeOCOCl, Et3N, PI1CH3, 70 °C, 18h.
The reaction mixture was stirred at room temperature to begin with and the 
temperature was gradually increased until reaction began to take place. At 70 °C 
most of the starting material had reacted, with only a small amount remaining. The 
mixture was then heated at reflux to see if this would drive the reaction to 
completion. However, little difference was observed on refluxing. Optimum yields 
of 87 were obtained when the mixture was stirred at 70 °C overnight.
Having successfully obtained the protected reduced dipeptides 82 and 87 in 
reasonable yields, the plan was now to work on the carboxy terminals of both to 
form aldehydes there, as in compounds 88a,b so that reductive amination reactions 
could be carried out (Scheme 5.15) in order to form the second reduced amide bond. 













a: R = CH3, P = Z 
b :R  = CH2Ph,P = Ac
Scheme 5.15. (i) Et3N, THF, AcOH, 3 A molecular sieves then NaBH(OAc)3 (ii) 
deprotection.
There are examples in the literature of the direct conversion of carboxylic 
esters to a l d e h y d e s  125 and, more specifically, of /-butyl esters to a l d e h y d e s .  126 
However, due to concerns about unwanted side reactions because of the variety of 
functional groups in the protected reduced dipeptides 82 and 87, these direct 
conversion methods were not attempted. Instead, the aim was to convert the /-butyl 
esters to their acids, which could then be transformed to aldehydes using the 
previously tried and tested method of Fehrentz and Castro. 105 Accordingly, work 
was carried out as in Scheme 5.16.
-74-








Scheme 5.16. (i) TFA, CH2CI2 , r .t, 72h (ii) N, O-dimethylhydroxylamine.HCl, 
EDC, Et3N, CH2CI2 , r .t, 72h (iii) LiAlH4 , IHF, 0 °C to r .t, 15 min then KHSO4 
(aq).
Removal of the t-butyl ester using trifluoroacetic acid was straightforward, 
giving the acid 91 in quantitative yield. The acid was then coupled with N, O- 
dimethylhydroxylamine hydrochloride using E D C .  107 Reaction was rather slow, as 
is commonly found with E D C  coupling reactions,*** and it was necessary to add two 
equivalents of E D C  and N, O-dimethylhydroxylamine hydrochloride over a period 
of 72 hours in order to drive the reaction to completion. This gave the desired N- 
methoxy-N-methylamide, 92.
The next step was LiAlH4 reduction of this N-methoxy-N-methylamide to 
give the aldehyde 88a. There was reason to believe that this transformation could be 
carried out without effecting any unwanted side reactions, despite the functionality 
present in 92. Toluenesulphonamides are known to be stable to LLAIH4  except at 
elevated temperatures {i.e. > 120 ° C ) . * * 3  From previous experience with LiAlH4 
reduction of methyl N-benzyloxycarbonyl-L-alanyl-L-alaninate, 16 and N-(f- 
butoxycarbonyl)-L-alanine-N-methoxy-N-methylamide, 65, we knew that urethane 
protecting groups were stable to LiAlH4 , at least at moderate temperatures.
Apparently, therefore, there should be no problem with LiAlH4 reduction of 
the N-methoxy-N-methylamide, 92 and so the reduction was carried out in the same 
way as reduction of N-(f-butoxycarbonyl)-L-alanine-N-methoxy-N-methylamide, 
65.105 ^ e  reaction was monitored by TLC and quenched after 15 minutes since all 
the starting material had been used up.
Unfortunately, however, the reaction was unsuccessful. It was evident from 
the *H NMR that a mixture of products was present, including a very small amount 
of aldehyde. It was thought that perhaps the desired aldehyde was being formed but 
was decomposing under the reaction conditions.
The failure of this reaction made it impossible to carry on with the proposed 
pathway. Attention was therefore turned to the other orthogonally protected reduced 
dipeptide, 82, which was available to see if it could be successfully transformed to 

















Scheme 5.17. (i) TFA, CH2CI2, r .t, 3.5h (ii) N, 0 -dimethylhydroxylamine.HCl, 
EDC, Et3N, DMF, r .t, 96h (iii) UAIH4 , THF, 0 °C to r .t, 10 min then KHSO4 
(aq).
Removal of the /-butyl ester as before proved straightforward. The resulting 
acid, 93 was converted to its N-methoxy-N-methylamide, 94 in 46% yield by EDC
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c o u p l i n g  107 with N ,  O-dimethylhydroxylamine hydrochloride. Once again it was
necessary to add two equivalents of EDC and N, O-dimethylhyroxylamine 
hydrochloride over the 96 hours to drive the reaction to completion.
Having successfully obtained the N-methoxy-N-methylamide, 94, the aim 
was now to convert it to aldehyde 88b by LiAlH4 reduction. As before, the tosyl 
group was not thought likely to cause any problems. The major concern here was 
that the N-acetyl group might interfere in the reaction since this reaction is 
dependent upon chelation of the lithium ion. Reduction of the N-acetyl group was 
not a concern, on two counts:
1. since reaction was likely to be complete in less than 20 minutes, the N-acetyl 
group could well be expected to survive;
2 . even if the acetyl group was reduced (to its ethyl derivative), the proposed 
pathway could be continued by way of a feasibility study even though final 
deprotection to give the target reduced tripeptide would be impossible.
In the case of a simple N-methoxy-N-methylamide e.g. N-(f- 
butoxycarbonyl)-L-alanine-N-methoxy-N-methylamide, 65 the reaction mechanism 





Scheme 5.18. (i)LiAlH4 (ii)H20.
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However, in the N-methoxy-N-methylamide, 94, there are potentially two 
ways in which the lithium ion could be chelated. These are shown in Figure 5.4.
Figure 5.4.
Having considered both of these possibilities, it was thought that the desired 
chelation was more likely to occur. LiAlH4 reduction was, therefore, carried out as 
before, but again, the reaction failed. The *H NMR showed that a mixture of 
products was present, including a very small amount of aldehyde. This could be 
taken as further evidence that, in reactions of this type, an aldehyde is formed but 
decomposes under the reaction conditions.
In conclusion, aldehydes 88a,b  were not isolated from these reactions 
although their existence is evident from the mass spectral data and, to some degree, 
from the *H NMR data obtained for these reaction mixtures. It remains to be proven 
whether these aldehydes are inherently unstable or merely unstable under the 
reaction conditions in question.
In order to determine this, it would be necessary to form the aldehydes via a 
completely different route, perhaps directly from the f-butyl esters (Scheme 5.20) or 
by reduction of these esters to alcohols followed by S w em ^? or pyridinium 
chlorochromatel28 oxidation (Scheme 5.21).
87 ,88a: R = CH3, P = Z 
82,88b:R = CH2Ph,P = Ac
Scheme 5.20. (i) LiAlH4 in THF, Et2NH^ 5  (ii) triethyl orthoformate, TFA.1^6
TsNH TsNH
R O R O
TsNH TsNH
87 or 82 88a, b
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TsNH TsNH OH





87 ,95a, 88a: R = CH3, P = Z 
82 ,95b, 88b: R = CH2Ph, P = Ac 
Scheme 5.21. (i) reduction (ii) oxidation.
Conclusion
Conclusion
A number of attempts were made to extend some of the existing methodology for 
the synthesis of secondary amines and reduced dipeptides to form a reduced 
tripeptide such as 71.
The reductive amination of an N-(r-butoxycarbonyl)amino aldehyde with an 
amino acid ester and the reaction of a di-tosylate with an amino acid ester were 
found to be good methods for the preparation of reduced dipeptides. Unfortunately, 
neither method could be satisfactorily extended within the time available to produce 
a reduced tripeptide in reasonable yield.
The novel tripeptide mimetic 71 was formed via reductive amination in a 
disappointing 2% yield.
Extensive functional group protection chemistry is required for the synthesis of 








All glassware was thoroughly dried before use.
Solvents
Dichloromethane was distilled from phosphorus pentoxide.
DMF was fractionally distilled under water pump vacuum with a nitrogen bleed.
Ether, which refers to diethyl ether, and THF were pie-dried over sodium wire and 
then distilled from sodium/benzophenone ketyl in an inert atmosphere prior to use. 
Ethyl acetate was distilled from potassium carbonate.
Methanol was distilled from Mg/l2.
Petroleum ether, which refers to the fraction boiling in the range 60 - 80 °C was 
distilled before use.
Toluene was pre-dried over sodium wire and then distilled from sodium in an inert 
atmosphere before use.
Reagents
Pyridine was distilled from calcium hydride.
Triethylamine was distilled from lithium aluminium hydride.
Chromatography
Reactions were monitored by TLC on Whatman aluminium backed UV254 silica gel 
plates. The chromatograms were viewed under UV light and visualised using a PMA 
solution (6% in 95% ethanol).
Flash column chromatography was carried out under medium pressure on Amicon 60 
A silica gel. The columns were packed with a slurry of silica in the initial eluent and 
the substrates were applied preabsorbed onto silica.
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Analysis and spectroscopy
Melting points were recorded on an Electrothermal apparatus and are uncorrected. 
Elemental analyses were recorded on a Carlo Erba 1106 Elemental Analyser.
Optical rotations were recorded on a Perkin-Elmer 141 Polarimeter at 20 °C.
IR spectra were recorded on a Perkin-Elmer 1600 Series FT IR instrument. 
lH  NMR spectra were recorded at 270 MHz and NMR at 67.8 MHz on a Jeol 
JNM-GX270 instrument or at 400 MHz and 100.4 MHz on a Jeol JNM-EX400 
instrument. Spectra were recorded at room temperature unless otherwise stated. 
Coupling constants are given in Hz. The assignment of ^ C  NMR was assisted by 
DEPT experiments.
Mass spectra were recorded on a VG Analytical 7070E instrument. For FAB spectra, 
NBA was used as the matrix. El spectra were recorded with an ionising potential of 
70eV.
Experimental procedures
N-Benzyloxycarbonyl-L-alanine , 15.- L-Alanine (5.25 g, 59.0 mmol) was 
dissolved in a 4M sodium hydroxide solution (14.75 ml, 59.0 mmol). 
Benzylchloroformate (8.41 ml, 59.0 mmol) and 4M sodium hydroxide (14.75 ml, 
59.0 mmol) were added dropwise simultaneously to the solution and the mixture was 
stirred at room temperature overnight before being washed with ethyl acetate. The 
aqueous layer was acidified with conc. hydrochloric acid to ~pH 2 then extracted with 
ethyl acetate. The combined extracts were dried over sodium sulphate, filtered and 
concentrated in vacuo. The crude product was crystallised from ethyl acetate- 
petroleum ether, leaving 15 (7.23 g, 55%) as a colourless solid, mp 84 - 86 °C 
( l i t . , g 7 o q ;  Rf o . l l  (chloroform-methanol-acetic acid, 90:8:2). vm ax 
(Nujol)/cm-l 3331 (NH), 3037 - 2837 (OH), 1708 (C0OH), 1682 (CON). 3h  
(DMSO) 1.27 (3H, d, J  7, C i/3), 4.02 (1H, q, J  7, C//CH3), 5.03 (2H, s, ArC//2),
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7.15 - 7.36 (5H, m, AiH), 7.62 (1H, d, /  7, NH). dQ (DMSO) 17.20 (CH3), 49.36 
(CH), 65.48 (CH2), 127.87, 127.92, 128.46 (Ar-CH), 137.15 (ArQ, 155.98 (CON), 
174.51 (COOH). mlz (FAB) 224 ([M+H]+, 33%), 180 ([M-COOH]+, 14).
M ethyl N -benzyloxycarbonyl-L-alanyl-L-alaninate , 16.- Method 1: N- 
Benzyloxycarbonyl-L-alanine, 15 (10.19 g, 45.6 mmol) and L-alanine methyl ester 
hydrochloride (6.36 g, 45.6 mmol) were dissolved in THF (100 ml) and the solution 
was cooled in an ice/salt bath. Triethylamine (6.36 ml, 45.6 mmol), HOBt (6.17 g, 
45.6 mmol) and DCC (9.41 g, 45.6 mmol) were added with stirring. Stirring was 
continued under an atmosphere of nitrogen overnight and during this time the mixture 
was allowed to warm up to room temperature. The DCU precipitate was filtered off 
and extracted with ethyl acetate (to ensure none of the product peptide was removed). 
The combined extracts, together with the filtrate which was dissolved in ethyl acetate 
were washed sequentially with a 5% citric acid solution, a 5% sodium hydrogen 
carbonate solution and water then dried over sodium sulphate, filtered and 
concentrated in vacuo. The crude product was purified by column chromatography 
(ethyl acetate-petroleum ether, 1:1) leaving 16 (8.48 g, 60%) as a colourless solid, mp 
108 - 110 °C (lit., 130 104 - 105 °C); Rf 0.54 (ethyl acetate-petroleum ether, 1:1). 
Found: C, 58.5; H, 6.7; N, 9.1. C15H20N2O5 requires: C, 58.4; H, 6.5; N, 9.1%. 
Vmax (Nujol)/ cm' 1 3034 (NH), 1751 (COOCH3), 1688 (CH2 OCON), 1642 
(CONH). 3 h  (CDCI3) 1.37 (3H, d, / 7 ,  CHCH3X 1.38 (3H, d , / 7 ,  CHCH3), 3.73 
(3H, s, COCH3), 4.33 (1H, q, J  7, CHCH3), 4.55 (1H, q, J  7, CHCH3), 5.10 (2H, 
s, ArCf/2). 5.67 (1H, d, J  8, NH), 6.92 (1H, d, J  7, NH), 7.27 - 7.34 (5H, m , 
ArH). 3 c  (CDCI3) 18.00, 18.65 (CHCH3), 47.95, 50.27 (CH), 52.37 (OCH3), 
66.86  (C H 2 ), 127.92, 128.07, 128.43 (Ar-CH), 136.16, (ArC), 155.85 
(CH2OCON), 171.95,173.09 (CO), mlz (FAB) 309 ([M+H]+, 55%).
Method 2: N-Benzyloxycarbonyl-L-alanine, 15 (0.98 g, 4.39 mmol) and N-
hydroxysuccinimide (1.03 g, 8.92 mmol) were dissolved in acetonitrile (12 ml). EDC 
(0.87 g, 4.52 mmol) was added to this solution and the mixture was stirred at room
temperature under an atmosphere of nitrogen. After 1.5h, more EDC (0.87 g, 4.52 
mmol) was added and stirring was continued for a further 2h. L-Alanine methyl ester 
hydrochloride (0.77 g, 5.50 mmol) and triethylamine (0.74 ml, 5.31 mmol) were then 
added and the mixture was stirred for 48h before being dissolved in ethyl acetate and 
washed sequentially with water, 5% sodium hydrogen carbonate solution, water, 1M 
hydrochloric acid and water. The organic phase was then dried over sodium sulphate, 
filtered and concentrated in vacuo to give a crude solid which was crystallised from 
ethyl acetate-petroleum ether, leaving 16 (0.31 g, 23%) as a colourless solid (data as 
above).
N-Benzyloxycarbonyl-L-alanyl-L-alanine, 17.- Methyl N-benzyloxycarbonyl-L- 
alanyl-L-alaninate, 16 (5.05 g, 16.4 mmol) was dissolved in methanol (100 ml). 
Water (100 ml) and lithium hydroxide monohydrate (1.55 g, 36.9 mmol) were added 
to the solution. The mixture was stirred at room temperature for 4h before being 
concentrated in vacuo, washed with ether then acidified to ~ pH 2 using conc. 
hydrochloric acid and extracted with ethyl acetate. The combined extracts were dried 
over sodium sulphate, filtered and evaporated to dryness, leaving 17 (3.97 g, 82%) as 
a colourless solid, mp 147 - 148 °C ( l i t , 149 - 151 °C); Rf 0.48 (chloroform- 
methanol-acetic acid, 90:8:2). vmax (Nujol)/cm"l 3331 (NH), 3000 - 2800 (OH), 
1690 (CH2OC0 N), 1649 (CONH). 9h  (DMSO) 1.12 (3H, d, J  7, CHCH3), 1.19 
(3H, d, J  7, CHCi/3), 4.00 (1H, q, J  7, Ctf CH3), 4.11 (1H, q, J 7, C//CH3), 4.93 
(2H, s, ArC//2), 7.21 - 7.31 (5H, m, Artf), 7.35 (1H, d, J  8, Ntf), 8.06 (1H, d, J  
7, NH). d c  (DMSO) 17.27, 18.27 (CH3), 47.51, 49.82 (CH), 65.44 (CH2 ),
127.81, 127.87, 128.44 (Ar-CH), 137.17 (ArC), 155.73 (CH2 OCON), 172.41, 
174.13 (CO).
M ethyl N -benzyloxycarbonyl-L -alanyl-L -alanyl-L -alaninate , 18.- N- 
Benzyloxycarbonyl-L-alanyl-L-alanine, 17 (2.44 g, 8.30 mmol) and L-alanine methyl 
ester hydrochloride (1.19 g, 8.49 mmol) were dissolved in THF (50 ml). The
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solution was cooled in an ice/salt bath and then triethylamine (1.18 ml, 8.49 mmol), 
HOBt (1.14 g, 8.44 mmol) and DCC (1.76 g, 8.53 mmol) were added. The mixture 
was stirred overnight under an atomosphere of nitrogen and during this time, it was 
allowed to warm up to room temperature. The DCU precipitate was then filtered off 
and extracted with ethyl acetate. The filtrate was dissolved in ethyl acetate and 
together with the combined extracts, washed sequentially with a 5% citric acid 
solution, a 5% sodium hydrogen carbonate solution and water then dried over sodium 
sulphate, filtered and concentrated in vacuo. The crude product was purified by 
column chromatography (ethyl acetate) to leave 18 (1.82 g, 58%) as a colourless 
solid, mp 166 - 168 °C (lit.,132 166 - 167 °C); Rf 0.45 (ethyl acetate). Found: C, 
57.0; H, 6.6; N, 11.2. C18H25N3O6 requires: C, 57.0; H, 6.6; N, 11.1%. vmax 
(Nujol)/cm-l 3270 (hr, NH), 1736 (COOCH3), 1694 (CH2OCON), 1640 (hr, 
CONH). 3 h  (CDCI3) 1.36 (9H, d, /  7, 3 X CHCH3), 3.70 (3H, s, OCH3), 4.39 
(1H, q, J  7, C//CH3), 4.54 (1H, q, J  7, CWCH3), 4.64 (1H, q, J  7, CHCH3), 5.10 
(2H, s, A1CH2 ), 5.94 (1H, d, J  7, NH), 7.27 - 7.33 (5H, m, AiH). d c  (CDCI3) 
17.97, 18.45, 18.93 (CHCH3), 48.04, 48.75, 50.48 (CH), 52.38 (OCH3), 66.90 
(CH2), 127.96, 128.10, 128.44 (Ar-CH), 136.18 (ArC), 156.36 (CH2 OCON),
171.81, 173.11 (CO), mlz (FAB) 380 ([M +H]+, 50%), 277 ([M- 
NHCH(CH3)COOMe]+, 18).
Methyl 2 'S-N-(2 '-benzyloxycarbonylamino)propyl-L-alaninatey 23.- Methyl N- 
benzyloxycarbonyl-L-alanyl-L-alaninate, 16 (0.30 g, 0.98 mmol) was dissolved in 
THF (10 ml) and the solution cooled to -78 °C. A 1M solution of borane.THF 
complex in THF (9.80 ml, 9.80 mmol) was added dropwise with stirring. The 
mixture was stirred under an atmosphere of nitrogen at -78 °C for lh then at 0 °C for 
a further 8h before being quenched by the addition of methanol (10 ml) and 1M 
hydrochloric acid (10 ml). After stirring for 15 min, the pH of the mixture was 
adjusted to ~8 with a 5% sodium hydrogen carbonate solution and the THF was 
removed in vacuo. The remaining solution was extracted with dichloromethane and
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the combined extracts were dried over sodium sulphate, filtered and concentrated in 
vacuo to give a crude oil which was purified by column chromatography (ethyl 
acetate-petroleum ether, 1:4 to ethyl acetate), leaving unreacted 16 (36 mg) and 23 (6 
mg, 2%) as a colourless oil; Rf 0.56 (ethyl acetate). vmax (CDCl3)/cm 'l 3430 (br, 
NH), 1750 (CH2OC0 N), 1717 (COOCH3). 3h  (CDCI3) 1.10 (3H, d, J  7, 
C H C //3), 1.21 (3H, d, J  7, CHC//3), 2.41 (1H, dd, /  7, -12, HC//N), 2.61 (1H, 
dd, J  7, -12, HC//N), 3.23 (1H, q, J  7, C//CH3), 3.64 (3H, s, OC//3), 3.68 (1H, 
q, J  6, C//CH3), 5.02 (2H, s, 0 /2 ) , 7.19 - 7.30 (5H, m, AiH). 3 c  (CDCI3) 18.80, 
18.97 (CHCH3), 51.88 (OC//3), 52.54 (CH2N), 56.73 (CH), 66.57 (PI1CH2O),
128.09, 128.51,128.84 (Ar-CH), 136.63 (ArC), 156.43 (CON), 175.84 (COOCH3). 
mlz (FAB) 295 ([M+H]+, 100%). Found: [M+H]+ 295.166000. C15H23N2O4 
requires: 295.165782.
N-Benzyloxycarbonyl-L-alanyl-L-alaninol, 30.- A solution of methyl N- 
benzyloxycarbonyl-L-alanyl-L-alaninate, 16 (0.64 g, 2.08 mmol) in THF (8 ml) was 
added dropwise to lithium aluminium hydride (0.24 g, 6.24 mmol) at 0 °C. The 
mixture was stirred under an atmosphere of nitrogen for 2h, during which time it was 
allowed to warm up to room temperature. Reaction was quenched by the addition of a 
saturated sodium sulphate solution and then evaporated to dryness to leave a white 
solid which was extracted with dichloromethane. The combined extracts were 
concentrated in vacuo leaving a crude oil which was purified by column 
chromatography (ethyl acetate-petroleum ether, 1:1 to ethyl acetate) to give 30 (0.27 g, 
47%) as a colourless solid, mp 143 - 145 °C; Rf 0.39 (ethyl acetate); [a]D -22.6 (c 
0.93, CH2CI2). Found: C, 60.2; H, 7.1; N, 9.75. C14H20N2O4  requires: C, 60.0; 
H, 7.2; N, 10.0%. v max (CDCl3)/cm -l 3515 (OH), 3323, 3267 (NH), 1668 
(CH2OCON), 1640 (CONH). 3h  (CDCI3) 1.14 (3H, d ,J7 , CH3), 1.38 (3H, d, J  7, 
CH3), 2.90 (1H, br s, OH), 3.44 - 3.54 (1H, m, HCHOH), 3.58 - 3.66 (1H, m, 
HCHOH), 3.98 - 4.04 (1H, m, CHCH3), 4.16 - 4.24 (1H, m, CHCH3), 5.10 (2H, 
s, PhCtf20), 5.46 (1H, d, J  7, NH), 6.39 (1H, br s, NH), 7.30 - 7.38 (5H, m,
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A tH). d c  (CDCI3) 16.78, 18.55 (CH3), 47.70, 50.78 (CH), 66.45, 67.12 (CH2),
128.10, 128.28, 128.55 (Ar-CH), 136.03 (ArC), 156.11 (CH2 OCO), 172.68 
(CONH). mlz (FAB) 281 ([M+H]+, 100%).
L-Phenylalaninol, 48.- Method 1 : L-Phenylalanine (165 g, 1.0 mol) was added to 
a stirred suspension of sodium borohydride (100 g, 2.5 mol) in THF (1 L). The flask 
was cooled in an ice/salt/water bath and a solution of conc. sulphuric acid (66 ml, 1.25 
mol) in ether (134 ml) was added dropwise, ensuring that the temperature stayed 
below 20 °C. Addition was completed in ~3h. The mixture was then allowed to 
warm up to room temperature and stirring was continued overnight Methanol (100 
ml) was added dropwise at 0 °C and the mixture concentrated to a volume of ~500 ml. 
A 5M sodium hydroxide solution (1 L) was added and the mixture refluxed for 3h, 
cooled, then filtered through Celite which was washed with water. The filtrate and 
washings were combined, diluted with additional water and extracted with 
dichloromethane. The combined extracts were dried over sodium sulphate, filtered 
and the dichloromethane removed in vacuo, leaving a crude white solid which was 
recrystallised from toluene to give 48 (12.87 g, 9%) as a colourless solid, mp 90 - 92 
°C Git,94  90 - 91 °C). Found: C, 71.5; H, 8.6; N, 9.4. C9H 13NO requires: C, 
71.5; H, 8.7; N, 9.3%. vmax (KBrVcm*1 3358 & 3306 (NH2), 3125 (br, OH). 3h  
(CDCI3) 1.83 (3H, br s, NH2  & OH), 2.52 (1H, dd, J  8, -12, HCHPh), 2.80 (1H, 
dd, J  4, -12, HCHPh), 3.09 - 3.15 (1H, m, CHNH2 ), 3.39 (1H, dd, /  8 , -12, 
HCHOH), 3.64 (1H, dd, J  4, -12, HCHOH), 7.18 - 7.33 (5H, m, ArH). 3c  
(CDCI3) 40.53 (CH2Ph), 54.21 (CH), 65.88 (CH2OH), 126.37, 128.43, 129.33 
(Ar-CH), 138.70 (ArC). mlz (FAB) 152 ([M+H]+, 100%).
Method 2 : Chlorotrimethylsilane (76 ml, 0.60 mol) was added dropwise with 
stirring to a 2M solution of lithium borohydride in THF (150 ml, 0.30 mol) over a 
period of 1.5h. L-Phenylalanine (25 g, 0.15 mol) was then added in small portions 
over a period of 4h. The mixture was stirred at room temperature under an atmosphere 
of nitrogen for 18h before being quenched by the addition of methanol (150 ml) and
then 20% potassium hydroxide solution (112 ml). The methanol was removed in 
vacuo and water (150 ml) was added to the residue. The resulting solution was 
extracted with dichloromethane and the combined extracts washed with water. The 
organic phase was dried over sodium sulpahte, filtered and the dichloromethane 
evaporated to leave 48 (11.3 g, 49%) as a colourless solid. Data as above.
N-Phthaloyl-L-phenylalaninol, 49.- L-Phenylalaninol, 48 (3.42 g, 22.6 mmol) and 
phthalic anhydride (3.61 g, 24.3 mmol) were heated a t-140 °C under an atmosphere 
of nitrogen for 2h. The mixture was allowed to cool and then dissolved in ethyl 
acetate and washed sequentially with 10% potassium carbonate solution, water, 2M 
hydrochloric acid, water and saturated brine. The organic phase was then dried over 
sodium sulphate, filtered and concentrated in vacuo to give a crude product which was 
purified by column chromatography (ethyl acetate-petroleum ether, 1:2), leaving 49 
(3.92 g, 62%) as a colourless solid, mp 103 - 105 °C (lit.,133 108.5 - 110 °C); Rf 
0.59 (ethyl acetate-petroleum ether, 1:2); [a]D -130.4 (c 0.79, CH2CI2) [ lit,133 _io8 
(c 2.44, EtOH)] . Found: C, 72.2; H, 5.4; N, 4.9. C17H15NO3 requires: C, 72.6; 
H, 5.4; N, 5.0%. vmax (KBr)/cnrl 3290 (br, OH), 1706 (CO), d u  (CDCI3) 3.21 
(2H, d, /  8, CH2PI1), 3.93 (1H, dd J  3, -12, HCHOH), 4.08 (1H, dd, J  7, -12, 
HCHOH), 4.62 - 4.66 (1H, m, CH), 7.15 - 7.23 (5H, m, ArH), 7.67 - 7.80 (4H, m, 
ArH). dc  (CDCI3) 34.74 (CH2PI1), 55.22 (CH), 62.71 (CH2O), 123.26, 126.62, 
128.49, 128.99 (Ar-CH), 131.55 (ArC), 134.03 (Ar-CH), 137.39 (ArC), 168.93 
(CO), mlz (FAB) 282 ([M+H]+, 71%), 264 ([M-OHJ+, 25).
Methyl N-trifluoroacetyl-L-phenylalaninate, 50.- Trifluoroacetic anhydride (1.75 
ml, 12.5 mmol) was added dropwise with stirring to a mixture of L-phenylalanine 
methyl ester hydrochloride (2.24 g, 10.4 mmol) and pyridine (2.52 ml, 31.2 mmol) in 
dichloromethane (50 ml). The mixture was stirred for 3h under an atmosphere of 
nitrogen at room temperature before being washed with 2M hydrochloric acid and 
water, dried over sodium sulphate, filtered and evaporated to dryness. The crude
product was purified by column chromatography (ethyl acetate-pentane, 1:6 to 1:5) 
giving 50 (1.71 g, 60%) as a colourless solid, mp 51 - 52 °C (lit.,96 53 - 54 o q ; R f 
0.55 (ethyl acetate-petroleum ether, 1:5); [a]D -9.9 (c 1.0, EtOH 95%) [lit,96 -9.9 (c 
1.0, EtOH 95%)]. Found: C, 52.35; H, 4.3; N, 4.9. C12H 12NO3F3 requires: C, 
52.4; H, 4.4; N, 5.1%. vmax (KBrVcnr1 3296 (NH), 1751 (COOCH3), 1704 
(CONH). du  (CDCI3) 3.17 (1H, dd, J  4, -12, HCf/Ph), 3.27 (1H, dd, /  4, -12, 
HCHPh), 3.79 (3H, s, C//3), 4.86 - 4.91 (1H, m, CH), 6.77 (1H, br s, NH), 7.04 -
7.08 (2H, m, AiH), 121  - 7.34 (3H, m, AiH). d c  (CDCI3) 37.26 (CH2 ), 52.87 
(CH3), 53.52 (CH), 116.68 (CF3), 127.63, 128.85, 129.17 (Ar-CH), 134.54 (ArC), 
156.69 (CONH), 170.38 (COOCH3). mlz (El) 276 ([M+H]+, 10%), 180 ([M- 
CF3CO]+, 9).
Methyl N-benzyl-N-trifluoroacetyl-L-phenylalaninate, 51.- 
N, N, N', N'-Tetramethylazodicarboxamide (0.09 g, 0.5 mmol) was added with 
stirring to a solution of benzyl alcohol (0.04 g, 0.33 mmol), tributylphosphine (0.12 
ml, 0.50 mmol) and methyl N-trifluoroacetyl-L-phenylalaninate, 50 (0.14 g, 0.50 
mmol) in toluene (10 ml) at 0 °C. The mixture was stirred under an atmosphere of 
nitrogen at 0 °C for 10 min and then overnight at room temperature. The precipitate 
was filtered off and the toluene removed in vacuo. The crude product was purified by 
column chromatography (ethyl acetate-pentane, 1:19) to give 51 (19 mg, 11%) as a 
colourless oil. Found: C, 62.7; H, 5.2; N, 3.9. C i9HigNC>3F3 requires: C, 62.5; 
H, 5.0; N, 3.8%. Vmax (liq- film)/cnrl 1750 (COOCH3), 1694 (CON). 3 h  (CDCI3) 
3.29 (1H, dd, J  10, -14, HO/Ph), 3.40 (1H, dd, 74 , -14, H O /Ph), 3.50 (1H, d, J  
-16, NHO/Ph), 3.66 (3H, s, Cf/3), 3.89 (1H, dd, J  4,10, CH), 4.58 (1H, d, J  -16, 
NHCi/Ph), 7.05 - 7.11 (5H, m, AiH), 7.27 - 7.34 (5H, m, ArH). d c  (CDCI3) 
34.11 (CHCH2), 52.52 (CH3), 53.06 (NCH2), 61.77 (CH), 119.28 (CF3), 128.50, 
128.69, 128.71, 128.83, 128.90, 129.21 (Ar-CH), 133.32, 137.26 (ArC), 168.86 
(COOCH3). mlz (FAB) 366 ([M+H]+, 28%), 306 ([M-COOMe]+, 18).
l-B rom o-(S )-2 -ph tha loylam ino-3-phenylpropane , 63.- N-Phthaloyl-L-
phenylalaninol, 49 (0.25 g, 0.89 mmol) and carbon tetrabromide (0.39 g, 1.18 mmol) 
were dissolved in dichloromethane (10 ml). The solution was cooled in an ice bath 
and triphenylphosphine (0.35 g, 1.34 mmol) was added portionwise with stirring. 
The mixture was stirred under an atmosphere of nitrogen for 4h and then the solvent 
was removed in vacuo. The crude product was purified by column chromatography 
(ethyl acetate-pentane, 1:9) to give 63 (0.17 g, 55%) as a colourless solid, mp 159 - 
161 °C (lit, 134 164.5 °C); Rf 0.42 (ethyl acetate-pentane, 1:9). Found: C, 59.3; H, 
4.2; N, 4.0. C i7 H i 4 NC>2 Br requires: C, 59.3; H, 4.1; N, 4.1%. v m a x 
(CHCl3)/cm-l 1708 (CO). (CDCI3) 3.26 (1H, dd, 74 , -10, HC/ZPh), 3.30 (1H, 
dd, J  8, -10, HC//Ph), 3.69 (1H, dd, J  4, -8, HC//Br), 4.13 (1H, t, J  -8, H O /B r), 
4.75 - 4.82 (1H, m, O /) , 7.14 - 7.25 (5H, m, Ar//), 7.68 - 7.72 (2H, m, Ar//),
7.77 - 7.82 (2H, m, AiH). dc  (CDCI3) 31.82, 37.38 (CH2), 54.39 (CH), 123.33, 
126.93, 128.65, 128.83 (Ar-CH), 131.43 (ArC), 134.05 (Ar-CH), 136.73 (ArC), 
167.95 (CO), mlz (FAB) 344 ([M+H]+, 100%).
N-(t-Butoxycarbonyl)-L-alanine-N-methoxy-N-methylamide, 65.- EDC (15.67 g,
81.8 mmol) was added to a solution of N-(f-butoxycarbonyl)-L-alanine (15.48 g, 81.8 
mmol), N,0-dimethylhydroxylamine hydrochloride (7.10 g, 72.8 mmol) and 
triethylamine (10.1 ml, 72.8 mmol) in dichloromethane (200 ml). The mixture was 
stirred at room temperature under an atmosphere of nitrogen for 18h and then washed 
successively with water, 2M hydrochloric acid, water, a 5% sodium hydrogen 
carbonate solution and water. The organic layer was then dried over sodium sulphate, 
filtered and the dichloromethane removed in vacuo to give 65 (14.2 g, 75%) as a 
colourless solid, mp 149 - 150 °C ( lit ,^ ^  150 °Q ; Rf 0.50 (ethyl acetate-petroleum 
ether, 1:2). Found: C, 52.0; H, 8.9; N, 12.0. C10H20N2O4 requires: C, 51.7; H, 
8.7; N, 12.1%. vmax(CDCl3)/cm-l 1702 (tBuOCONH), 1655 (C0 N(CH3)OCH3).
(CDCI3 ) 1.24 (3H, d, /  7, CHC//3), 1.37 (9H, s, C(C//3 )3 ), 3.14 (3H, s, 
N C //3), 3.70 (3H, s, OC//3), 4.61 (1H, m, C//CH3), 5.20 (1H, d, J  7, NH). dc
-90-
(CDC13) 18.58 (CHCH3), 28.27 (C(CH3)3), 34.64 (CHCH3), 46.43 (CH3N), 61.45 
(OCH3), 79.40 (C(CH3)3), 155.10 (*BuOCONH), 173.59 (CONCH3). mlz (FAB) 
233 ([M+H]+, 85%), 177 ([M-*Bu]+, 100).
N-(t-Butoxycarbonyl)-L-alaninal,6 6 .- Lithium aluminium hydride (1.11 g, 29.2 
mmol) was added slowly to a solution of N-(r-butoxycarbonyl)-L-alanine-N-methoxy- 
N-methylamide, 65 (5.37 g, 23.1 mmol) in THF (200 ml) at 0 °C. The mixture was 
stirred at room temperature under an atmosphere of nitrogen for 20 mins before being 
quenched by the dropwise addition of a 0.35M potassium hydrogen sulphate solution 
(117 ml, 40.9 mmol). The resulting mixture was extracted with ether and the 
combined extracts were washed successively with 2M hydrochloric acid, saturated 
sodium hydrogen carbonate solution and saturated brine. The organic layer was then 
dried over magnesium sulphate, filtered and the ether removed in vacuo to leave 66 
(3.40 g, 86%) as a colourless solid, mp 84 - 87 °C (lit, 105 gg _ g9 o q . R f q.46 
(ethyl acetate-pentane, 1:4); [a]D +29.4 (c 1.11, CH2CI2 ) [ lit ,105 +35.7 (c 1.0, 
CH2CI2)]. Found: C, 55.8; H, 8.7; N, 8.1. C8H 15NO3 requires: C, 55.5; H, 8.7; 
N, 8.1%. vmax(KBr/cm-l) 1735 (C0H), 1685 (CONH). 9h  (CDCI3) 1.34 (3H, d , /  
8, CHC//3), 1.45 (9H, s, C(C//3)3). 4.20 - 4.28 (1H, m, C//(CH3)), 5.09 (1H, br 
s, NH), 9.57 (1H, s, CHO). dc  (CDCI3) 14.76 (CH3), 28.30 (C(CH3)3), 55.50 
(CHCH3), 80.04 (C(CH3)3), 155.40 (CONH), 199.98 (CHO). mlz (FAB) 174 
([M+H]+, 12%), 118 ([M-tBu]*, 72).
Methyl 2'(S)-N-(2'-t-butoxycarbonylamino)propyl-L-alaninate, 68a.- L-Alanine 
methyl ester hydrochloride (0.84 g, 6.02 mmol), triethylamine (0.84 ml, 6.02 mmol) 
and glacial acetic acid (0.31 ml, 5.43 mmol) were added to a solution of N-(f- 
butoxycarbonyl)-L-alaninal, 66 (0.94 g, 5.43 mmol) in THF (50 ml). The mixture 
was stirred at room temperature over powdered 3 A molecular sieves, under an 
atmosphere of nitrogen for lh. Sodium triacetoxyborohydride (1.61 g, 7.60 mmol) 
was then added and stirring was continued overnight. After this time, the mixture was
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diluted with THF, filtered to remove the molecular sieves and concentrated in vacuo. 
The residual oil was treated with a saturated sodium hydrogen carbonate solution to 
quench any unreacted sodium triacetoxyborohydride and then adjusted to -pH  10 with 
1M sodium hydroxide solution. Ethyl acetate was added, the layers separated and the 
aqueous layer extracted with ethyl acetate. The combined organic extracts were 
washed with water, dried over sodium sulphate, filtered and the solvent removed in 
vacuo to leave a yellow oil which was purified by column chromatography (ethyl 
acetate-pentane, 1:4 with 0.1% triethylamine) to give 68a as a colourless oil (0.55 g, 
39%); Rf 0.35 (ethyl acetate-petroleum ether, 1:2); [a]o  -22.4 (c 1.93, CH2CI2). 
Found: C, 55.7; H, 9.4; N, 10.6. C12H24N2O4 requires: C, 55.4; H, 9.3; N, 
10.8%. Vmax (liq- film)/cm-l 1740 (COOCH3), 1715 (tBuOCONH). (CDCI3) 
1.14 (3H, d, J  8, C //3), 1-30 (3H, d, 7 8, CZ/3), 1.44 (9H, s, C(C//3)3 ), 2.46 (1H, 
dd, J  6 , - 12, HCZ/NH2), 2.65 (1H, dd, J  4, -12, HCZ/NH2 ), 3.36 (1H, q, J  6 , 
C //C H 3), 3.67 (1H, m, C//CH3), 3.72 (3H, s, OC//3), 4.68 (1H, br s, NH). d c  
(CDCI3 ) 19.78, 19.96 (CH3), 29.31 (C(CH3)3), 46.60, 52.74 (CHCH3), 53.75 
(CH 2NH), 57.65 (OCH3 ), 79.20 (C(CH3)3), 156.60 (‘BuOCONH), 176.89 
(COOCH3). mlz (FAB) 261 ([M+H]+, 92%), 205 ([M-tBu]+, 100), 161 ([M- 
NCH(CH3)COOMe]+, 43).
Methyl 2'(S )-N-(2'-t-butoxy carbonyl amino )propyl-L-phenylalaninate, 68b.- L- 
Phenylalanine methyl ester hydrochloride (1.87 g, 8.67 mmol), triethylamine (1.21 
ml, 8.67 mmol) and glacial acetic acid (0.45 ml, 7.91 mmol) were added to a solution 
of N-(f-butoxycarbonyl)-L-alaninal, 66 (1.37 g, 7.91 mmol) in THF (80 ml). The 
mixture was stirred at room temperature over powdered 3 A molecular sieves under an 
atmosphere of nitrogen for lh. Sodium triacetoxyborohydride (2.35 g, 11.1 mmol) 
was then added and stirring continued overnight After this time, the mixture was 
diluted with THF, filtered to remove the molecular sieves and concentrated in vacuo. 
The residual oil was treated with a saturated sodium hydrogen carbonate solution to 
quench any unreacted sodium triacetoxyborohydride and then adjusted to -pH 10 with
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1M sodium hydroxide solution. Ethyl acetate was added, the layers separated and the 
aqueous layer extracted with ethyl acetate. The combined organics were washed with 
water, dried over sodium sulphate and concentrated in vacuo to leave an oil which was 
purified by column chromatography (ethyl acetate-pentane, 1:4), leaving pure 68b 
(1.54 g, 58%) as a colourless oil; Rf 0.32 (ethyl acetate-pentane, 1:4); [a]D -8.69 (c 
0.84, CH2CI2). Found: C, 64.2; H, 8.5; N, 8.5. C18H28N2 O4  requires: C, 64.3; 
H, 8.4; N, 8.3%. vmax Giq- film)/cm-l 3375 (NH), 1738 (COOCH3), 1716 
(C0NH). 3 h  (CDCI3) 1.05 (3H, d, J  8, CHCH3), 1.44 (9H, s, C(Ctf 3)3), 2.40 
(1H, dd, J  6 , -12, HCHNH), 2.64 (1H, dd, J  6 , -12, HCHNH), 2.89 (1H, dd, J  8, 
-14, HCHPh), 2.96 (1H, dd, J  8, -14, HCHPh), 3.48 (1H, dd, /  6 , 8, CHCH2Ph), 
3.61 (1H, br s, CHCH3 ), 3.66 (3H, s, OCH3), 7.16 - 7.31 (5H, m, ArH). d c  
(CDCI3 ) 18.91 (CHCH3), 28.43 (C(CH3)3), 39.53 (CH2 ), 46.33, 51.70 (CH), 
53.06 (CH2), 63.18 (OCH3), 79.00 (C(CH3)3), 126.71, 128.42, 129.16 (Ar-CH), 
137.35 (ArC), 155.60 (COOCH3), 174.84 (CONH). mlz (FAB) 337 ([M+H]+, 
82%), 281 ([M-tBu]+, 100).
M ethyl 2'(S)-N-(2'-amino)propyl-L-alaninate hydrochloride , 69a .- 1M 
Hydrochloric acid (2.5 ml, 2.50 mmol) was added to a solution of methyl 2'(S)-N- 
(2f-r-butoxycarbonylamino)propyl-L-alaninate, 68a (0.27 g, 1.04 mmol) in 1,4- 
dioxane (10 ml). The mixture was stirred at room temperature for lh  before being 
evaporated to dryness to leave 69a (0.19 g, 79%) as a hygroscopic solid; [a ]o  -10.3 
(c 1.20, MeOH). Found: C, 33.5; H, 8.0; N, 11.2. C7H 18N2O2CI2 .H2O requires: 
C, 33.5; H, 8.0; N, 11.2%. vmax Oiq- film )/cnrl 2523 (NH), 1747 (CO). 9 h  
(DMSO) 1.31 (3H, d, J  6, CHCH3), 1.51 (3H, d, /  6 , CHCH3), 3.11 - 3.31 (2H, ta­
rn, CH2 NH), 3.66 (1H, br s, CHCH3), 3.78 (3H, s, OCH3 ), 4.25 (1H, br s, 
CHCH3), 8.40 (3H, br s, NH). dc  03MSO) 14.06, 14.21 (CHCH3), 43.49, 44.09 
(CHCH3), 47.99 (CH2 ), 52.96 (OCH3), 169.47 (CO), mlz (FAB) 161 ([M+H]+, 
100%).
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Methyl 2'(S)-N-(2'-amino)propyl-L-phenylalaninate, 69b.- 1M Hydrochloric acid 
(3 ml, 3.0 mmol) was added to a solution of methyl 2'(S)-N-(2'-f- 
butoxycarbonylamino)propyl-L-phenylalaninate, 68b (0.20 g, 0.60 mmol) in 1,4- 
dioxane (10 ml). The mixture was stirred at room temperature for 2h and then 
evaporated to dryness, leaving 69b (0.20 g, quantitative yield) as a hygroscopic solid. 
Found: C, 47.5; H, 7.75; N, 8.6. C13H22N2O2CI2 requires: C, 47.7; H, 7.4; N, 
8.6%. Vmax (KBr)/cm-l 3430 & 2950 (NH), 1747 (CO). 9 h  (DMSO) 1.31 (3H, d, 
J  6, CHC//3), 3.13 - 3.23 (2H, m, C//2NH), 3.32 - 3.46 (2H, m, CH^PX), 3.63 
(3H, s, O C//3), 3.68 - 3.76 (1H, m, C//CH3), 4.40 - 4.46 (1H, m, C//CH 2PI1), 
7.26 - 7.38 (5H, m, A t//), 8.55 (2H, br s, N//). 3 c  (DMSO) 16.78 (CHCH3),
34.50 (CH2 ), 44.07 (CH), 48.85 (CH2 ), 52.55 (CH), 60.60 (OCH3), 127.24,
128.48, 129.28 (Ar-CH), 134.50 (ArC), 168.50 (CO), mlz (FAB) 237 ([M+H]+, 
100%).
Methyl 2 ’(S)-N-[2’(S)-N-(2t-butoxycarbonylamino)propyl]propyl-L-alaninate, 
71.- Methyl 2’(S)-N-(2'-amino)propyl-L-alaninate hydrochloride, 69a (0.19 g, 0.81 
mmol) was dissolved in glacial acetic acid (2 ml) and added slowly dropwise to a 
solution of N-(f-butoxycarbonyl)-L-alaninal, 66  (0.13 g, 0.74 mmol) and 
triethylamine (0.23 ml, 1.62 mmol) in THF (10 ml). The mixture was stirred over 
powdered 3 A molecular sieves under an atmosphere of nitrogen at room temperature 
for 1.5h. Sodium triacetoxyborohydride (0.22 g, 1.04 mmol) was then added and the 
mixture stirred for a further 4h before being filtered to remove the molecular sieves. 
The THF was removed in vacuo and the remaining oil quenched with a saturated 
sodium hydrogen carbonate solution then adjusted to ~ pH 10 with 1M sodium 
hydroxide solution and extracted with ethyl acetate. The combined extracts were 
washed with water, dried over sodium sulphate, filtered and the solvent removed in 
vacuo to leave a colourless oil which was purified by column chromatography 
(dichloromethane-methanol, 99:1 to 85:15). The desired product, 71 (5 mg, 2%) was 
obtained as a colourless oil. 3h  (CDCI3) 1.03 (3H, d, J  6, CHC//3), 1.15 (3H, d, J
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6 , CHC//3), 1.30 (3H, d, /  6 , CHCH3), 1.44 (9H, s, C(CH3)3), 2.27 - 2.35 (1H, 
m, HCHNH), 2.40 - 2.77 (5H, m, 5 X HCHNH), 3.25 - 3.38 (1H, m, CH), 3.72 
(3H, s, OCH3). mlz (FAB) 318 ([M+H]+, 100%).
Methyl N-benzyloxycarbonyl-2'(S)-N-(2'-t-butoxycarbonylamino)propyl-L- 
phenylalaninate , 72.- Methyl 2,(S)-N-(2’-f-butoxycarbonylamino)propyl-L- 
phenylalaninate, 68b (1.50 g, 4.45 mmol) was dissolved in dichloromethane (50 ml) 
and the solution cooled in an ice bath. To this solution was added 3M sodium 
hydroxide (50 ml) which had also been cooled to 0 °C. The heterogeneous mixture 
was stirred rapidly at 0 °C and benzylchloroformate (0.95 ml, 6.68 mmol) and a 
catalytic amount of benzyltriethylammonium chloride were added. Stirring was 
continued at 0 °C for lh and then the mixture was stirred at room temperature for a 
further 1.5h. After this time, the layers were separated and the aqueous layer extracted 
with dichloromethane. The combined organics were washed with 1M hydrochloric 
acid and water and then dried over sodium sulphate, filtered and the dichloromethane 
removed in vacuo. The crude product was purified by column chromatography (ethyl 
acetate-pentane, 1:9), leaving pure 72 (1.41 g, 67%) as a colourless oil; Rf 0.26 (ethyl 
acetate-petroleum ether, 1:4); [a]D -104.3 (c 2.65, CH2CI2). Found: C, 66 .2 ; H, 
7.3; N, 6.35. C2 6 H 3 4 N 2 O 6 requires: C, 66.4; H, 7.3; N, 5.95%. Vmax 
(]iq.film)/cm"l 1750 (COOCH3), 1709 (hr, teuOCO & PhCH2OC0). 9 h  (DMSO, 70 
°C) 0.80 (3H, d, J  6 , CHC//3 ), 2.94 (1H, dd, J  6 , -14, HCffN), 3.09 (3H, s, 
O C //3), 3.28 (1H, dd, 7 6 , -14, HCHN), 3.41 (1H, m, CH), 4.34 (1H, m, CH), 
5.05 - 5.12 (2H, m, Cff2Ph), 6.16 (1H, br s, NH), 7.11 - 7.39 (10H, m, AiH). dc  
(DMSO, 160 °C) 17.32 (CHCH3), 27.45 (C(CH3)3), 34.89 (CHCH2), 45.26 &
45.37 (CH), 50.71 (OCH3), 52.41 & 52.72 (CH2N), 61.56, 61.79 (CH), 66.05 
(OCH2Ph), 77.08 (C(CH3)3), 125.42, 126.77, 126.88, 127.28, 127.36, 128.14 (Ar- 
CH), 135.86, 137.19 (ArC), 154.07,155.03 (OCON), 169.73 & 169.88 (COOCH3). 
m/z (FAB) 471 ([M+H]+, 11%), 371 ([M-tBuCCO]-*-, 100).
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Methyl N-benzyloxycarbonyl-2 '(S)-N-(2amino)propyl-L-phenylalaninate, 73.- 
1M Hydrochloric acid (4 ml, 4.0 mmol) was added to a solution of methyl N- 
benzyloxycarbonyl-2’(S)-N-(2'-r-butoxycarbonylamino)propyl-L-phenylalaninate, 72 
(0.30 g, 0.64 mmol) in 1,4-dioxane (10 ml). The mixture was stirred at room 
temperature for 2h before being evaporated to dryness, leaving 73 (0.24 g, 92%) as a 
hygroscopic solid; [cc]d -85.9 (c 3.62, MeOH). vmax (CH2Cl2)/cm‘l 3402 (NH), 
1737 (COOCH3), 1702 (NCOO). du  (DMSO, 70 <>C) 0.94 & 1.08 (3H, d, J  6 , 
CHC//3), 2.92 - 3.34 (5H, m, C//2N, CH2 Ph & CH), 3.63 (3H, s, OCf/3)» 4.44 -
4.52 (1H, m, CH), 5.06 - 5.17 (2H, m, OC//2Ph), 7.10 - 7.42 (10H, m, AiH), 7.74 
(3H, br s, N //). d c  (DMSO, 70 °C) 15.54, 15.69 & 16.60 (CHCH3 ), 34.51 
(CHCH2 ), 45.63 & 45.75 (CH), 51.63 (OCH3), 60.71 & 62.09 (CH), 66.71 
(OCH2Ph), 126.15, 126.24, 126.92, 127.14, 127.37, 127.54, 127.69, 127.78,
128.05, 128.20, 128.25, 128.34, 128.78, 128.87, 129.06, 129.13 (Ar-CH), 136.01, 
137.09 (ArC), 153.55, 154.62 & 154.97 (PI1CH2OCON), 170.72, 170.77 & 171.98 
(COOCH3). mlz (FAB) 371 ([M+H]+, 100%). Found: [M+H]+ 371.197174. 
C21H27N2O4 requires: 371.197083.
1-Benzyloxycarbonyl-2-benzyl-3-oxo-5-methyl-piperazine, 75.- The hydrochloride 
salt of methyl N-benzyloxycarbonyl-2'(S)-N-(2'-amino)propyl-L-phenylalaninate, 73 
(0.23 g, 0.57 mmol) was dissolved in glacial acetic acid and added slowly dropwise to 
a solution of N-(r-butoxycarbonyl)-L-alaninal (0.09 g, 0.52 mmol) in THF. 
Triethylamine (0.08 ml, 0.57 mmol) was added and the mixture stirred over powdered 
3 A molecular sieves under an atmosphere of nitrogen at room temperature for 1.5h. 
Sodium triacetoxyborohydride (0.15 g, 0.73 mmol) was then added and stirring was 
continued overnight. The mixture was diluted with THF, filtered and the THF 
removed in vacuo. The residual oil was treated with a saturated sodium hyrogen 
carbonate solution to quench unreacted sodium triacetoxyborohydride and then 
adjusted to ~pH 10 with a 1M sodium hydroxide solution before being extracted with 
ethyl acetate. The combined extracts were washed with water, dried over sodium
sulphate, filtered and then concentrated in vacuo to leave a crude oil which was 
purified by column chromatography (ethyl acetate-pentane, 1:1). The desired product, 
BocAla\|/[CH2NH]Ala\|/[CH2NZ]PheOMe, was not obtained. The product of the 
reaction was a colourless oil, 75 (0.08 g, 44%); Rf 0.24 (ethyl acetate-petroleum 
ether, 1:1); [cc]d +59.5 (c 1.48, CH2 CI2 ). Found: C, 69.6; H, 7.2; N, 7.8. 
C20H22N2O3 .H2O requires: C, 70.0; H, 7.1; N, 7.8%. Vmax (liq.film)/cm“l 3037 
(NH), 1705 (CH2OCON), 1673 (CCNH). (DMSO, 60 o q  0.95 (3H, d, J  6 , 
CHC//3), 2.33 (1H, br s, HC//N), 3.05 (1H, dd, /  5, -14, HCf/Ph), 3.14 (1H, dd, 
J  8, -14, HO/Ph), 3.42 (1H, m, O /C H 3), 3.90 (1H, br s, H O /N ), 4.52 (1H, br s, 
0 /CH2Ph), 4.98 (2H, br s, COOO/2PI1), 7.09 - 7.12 (2H, m, AiH ), 7.16 - 7.24 
(5H, m, Ar//), 7.28 - 7.36 (3H, m, Ar//), 7.90 (1H, br s, NH). d c  (DMSO, 160 
°C) 18.07 & 20.00 (CH3), 36.39 (CHCH2), 45.50 & 46.67 (CH), 56.39, 57.10 
(CH2 ), 66.16 (CH), 126.15, 127.17, 127.21, 127.50, 127.81, 128.03, 129.08, 
129.15 (Ar-CH), 135.68, 137.10 (ArC), 153.64, 154.26 (OCON), 167.10 & 167.72 
(COOCH3). mlz (FAB) 339 ([M+H]+, 100%).
N,0-Di-tosyl-L-phenylalaninol, 76.- A solution of L-phenylalaninol, 48 (20.44 g, 
0.14 mol) and pyridine (68.0 ml, 0.84 mol) in dichloromethane (500 ml) was added 
dropwise to tosyl chloride (111 g, 0.58 mol) at 0 °C. The mixture was stirred under 
an atmosphere of nitrogen for 2h, during which time it was allowed to warm to room 
temperature, before being quenched with water and extracted with dichloromethane. 
The combined extracts were washed with 2M hydrochloric acid, a saturated sodium 
hydrogen carbonate solution and water and then dried over sodium sulphate, filtered 
and concentrated in vacuo. The resulting oil was triturated with ether to give 76 (43.2 
g, 70%) as a colourless solid, mp 98 - 99 °C (lit.,**6 98 - 99.5 °C); Rf 0.44 (ethyl 
acetate-petroleum ether, 1:2); [a]D -45.1 (c 1.07, CH2CI2) [ l it ,H 6 -63.4 (c 1.05, 
PhH)]. Found: C, 59.8; H, 5.45; N, 3.2; S, 13.6. C23H25NO5S2 requires: C, 
60.1; H, 5.5; N, 3.05; S, 13.95%. vmax (KBr)/cm‘ l 1370 & 1179 (SO2N), 1165 
(SO2O). 9 h  (CDCI3) 2.41 (3H, s, PhO /3), 2.48 (3H, s, PI1C //3), 2.67 (1H, dd, /
8 , -12, HCi/Ph), 2.82 (1H, dd, /  8, -12, HCi/Ph), 3.57 (1H, m, CifCH2Ph), 3.85 
(1H, dd, J  4, 10, HCi/OH), 3.97 (1H, dd, J  4, 10, HO/OH), 4.63 (1H, d, /  8, 
Nif), 6.86 - 6.90 (2H, m, AiH), 7.11 - 7.21 (5H, m, AiH  ), 7.37 (2H, d, /  8 , Arif),
7.53 (2H, d, /  8, Ari/), 7.76 (2H, d, J  8, Arii). 9 c  (CDCI3 ) 21.50, 21.68 
(CH3Ph), 37.51 (CH2Ph), 53.60 (CHCH2), 70.18 (CH2), 126.83, 126.86, 128.02,
128.66, 129.07, 129.66 (Ar-CH), 130.00, 132.17, 135.70, 136.71, 143.41, 145.22 
(ArC). mlz (FAB) 460 ([M+H]+, 17%), 306 ([M-CH3ArS02]+, 20), 185 ([M- 
CH3ArS0 2 NHCHCH2Ph]+, 34).
Methyl 2 '(S)-N-(2 '-tosylamino-3'-phenyl)propyl-L-alaninate, 77 and (S)-benzyl-l- 
tosyl-aziridXne, 78.- N,0-Di-tosyl-L-phenylalaninol, 76 (5.03 g, 10.9 mmol) was 
dissolved in dichloromethane (100 ml). To this solution, L-alanine methyl ester 
hydrochloride (1.74 g, 12.5 mmol) and diisopropylethylamine (3.8 ml, 21.8 mmol) 
were added. The mixture was stirred at room temperature overnight and then washed 
with water. The organic layer was dried over sodium sulphate, filtered and the solvent 
removed in vacuo to yield an oil consisting of 2 components. These were separated 
by column chromatography (ethyl acetate-pentane, 1:4 to 1:1) to give 77 as a 
colourless oil (0.56 g, 13%); Rf 0.16 (ethyl acetate-pentane, 1:2). Found: C, 61.4; 
H, 6.7; N, 7.3. C20H26N2O4S requires: C, 61.5; H, 6.7; N, 7.2%. Vmax (liq.- 
3288 (NH), 1740 (CO), 1335 & 1160 (S0 2 N). 9 h  (CDCI3) 1.40 (3H, d, 
J  8, CHCH3), 2.33 (1H, dd, J  6, -12, HCHNH), 2.41 (3H, s, CH3), 2.62 (1H, dd, 
J  4, -12, HCHNH), 2.75 (1H, dd, /  4, -12, HCHPh), 2.86 (1H, dd, J  6 , -12, 
HCHPh), 3.19 (1H, q, J  8 , CHCH3 ), 3.29 (1H, m, CHCH2PI1), 3.68 (3H, s, 
OCH3), 5.17 (1H, d, J  6, NH), 7.03 - 7.07 (2H, m, ArH), 7.17 - 7.27 (5H, m, 
ArH), 7.67 (2H, d, /  8, ArH). 3 c  (CDCI3) 18.90 (CHCH3), 21.52 (CH3), 39.28 
(CH2Ph), 49.52 (CH2NH), 51.89, 54.74 (CH), 56.55 (OCH3), 126.58, 127.20, 
128.50, 129.41 & 129.60 (Ar-CH), 137.03 & 140.32 (ArC), 170.55 (CO), mlz (El) 
391 ([M+H]+, 100%). The major product of the reaction, however, was 2(S)-benzyl-
l-(tosyl)-aziridine, 78 (1.0 g, 32%) which was obtained as a colourless solid, mp 92 -
94 °C after recrystallisation from methanol/water (lit.,116 92 - 94 °C); Rf 0.70 (ethyl 
acetate-pentane, 1:2). Found: C, 66.7; H, 6.0; N, 5.00; S, 10.90. C16H 17NO2S 
requires: C, 66.9; H, 6.0; N, 4.9; S, 11.2%. vmax (K B^/cnr1 1317 & 1163 (SO2). 
0H (CDCI3) 2.17 (1H, d, J  4, HC//N), 2.42 (3H, s, C //3PI1), 2.69 (1H, dd, /  6, 
-14, HO/Ph), 2.71 (1H, d, /  6, H O N ), 2.81 (1H, dd, J  4, -14, H O /Ph), 2.92 - 
2.98 (1H, m, OZCH2Ph), 7.03 - 7.06 (2H, m, Ar//), 7.12 - 7.18 (3H, m, Ar//), 
7.22 (2H, d, J  8, Ar//), 7.68 (2H, d, J  8, AiH). d c  (CDCI3) 21.62 (CH3), 32.38,
37.50 (CH2), 41.17 (CH), 126.50, 127.88, 128.45, 128.72, 129.58 (Ar-CH), 
129.76, 137.00, 144.30 (ArC). mlz (FAB) 288 ([M+H]+, 57%), 155 ([M- 
CH3ArS02]+, 37).
2-(S)’Benzyl-l-tosyl-aziridine,7&.- N, O-Di-tosyl-L-phenylalaninol, 76 (1.21 g, 
2.63 mmol) was dissolved in dichloromethane (7 ml). To this solution, triethylamine 
(0.37 ml, 2.63 mmol) was added dropwise with stirring. The mixture was stirred at 
room temperature under an atmosphere of nitrogen for 72h before being washed with 
2M hydrochloric acid and water then dried over sodium sulphate, filtered and 
concentrated in vacuo leaving a crude product which was purified by column 
chromatography (ethyl acetate-petroleum ether, 1:4) to give 78 (0.31 g, 41%) as a 
colourless solid. Data as above.
t-Butyl 2 YS)-N-(2 '-tosylamino-3 -phenyl)propyl-L-alaninate, 79.- N,O-Di-tosyl-L- 
phenylalaninol, 76 (11.08 g, 24.1 mmol) was dissolved in DMF (150 ml). To this 
solution was added L-alanine r-butyl ester hydrochloride (4.81 g, 26.5 mmol) and 
triethylamine (10.1 ml, 72.3 mmol). The reaction mixture was stirred under an 
atmosphere of nitrogen at 80 °C overnight The mixture was then dissolved in ethyl 
acetate, washed with water, dried over sodium sulphate, filtered and the ethyl acetate 
removed in vacuo. The crude product was purified by column chromatography (ethyl 
acetate-pentane, 1:6 to 1:2), leaving 79 (4.99g , 48%) as a colourless solid, mp 98 - 
101 °C; Rf 0.27 (ethyl acetate-pentane, 1:4); [<x]d +5.66 (c 1.02, CH2CI2). Found:
-99-
C, 63.9; H, 7.6; N, 6.5; S, 7.1. C23H32N2O4S requires: C, 63.9; H, 7.5; N, 6.5; 
S, 7.4%. vmax (KBr)/cnrl 3367, 3252 (NH), 1706 (CO), 1320, 1154 (SO2N). du  
(CDCI3) 1.15 (3H, d, J  8, CHC//3), 1.40 (9H, s, (0 /3)3), 2.31 (1H, dd, J  6, -12, 
HC//NH), 2.41 (3H, s, C//3Ph), 2.59 (1H, dd, 74 , -12, HC//NH), 2.75 (1H, dd, J  
8 , -14, HC//Ph), 2.91 (1H, dd, J  6, -14, HO/Ph), 3.04 (1H, q, J  6, O /C H 3), 3.21
- 3.29 (1H, m, C//CH2PI1), 5.24 (1H, d, J  6, N//), 7.04 - 7.09 (2H, m, Ar//), 7.16
- 7.27 (5H, m, AiH), 7.69 (2H, d, J  8, AiH). dc  (CDCI3) 18.87 (CHCH3), 21.50 
(CH 3Ar), 27.98 (C(CH3)3 ), 39.36, 49.30 (CH2 ), 54.87, 57.27 (CH), 81.13 
(C(CH3)3 ), 126.50, 127.19, 128.43, 129,38, 129.57 (Ar-CH), 136.67, 137.17, 
143.17 (ArQ, 174.63 (CO), mlz (El) 433 ([M+H]+, 100%).
t-Butyl 2 ’(S)-N-(2 ’-tosylamino-3 ’-phenyl)propyl-L-alaninate, 79.- 2-(S)-Benzyl-1 - 
tosyl-aziridine (0.10 g, 0.35 mmol) was dissolved in DMF (3 ml). L-Alanine r-butyl 
ester hydrochloride (0.07 g, 0.39 mmol) and triethylamine (0.10 ml, 0.70 mmol) were 
added to this solution and the mixture was stirred at 80 °C under an atmosphere of 
nitrogen overnight. The mixture was then dissolved in ethyl acetate, washed with 
water, dried over sodium sulphate, filtered and the ethyl acetate removed in vacuo. 
The crude product was purified by column chromatography (ethyl acetate-pentane, 1:4 
to 1:2) leaving 79 (68 mg, 45%) as a colourless solid. Data as above.
t-Butyl N-acetyl-2 ’(S)-N-(2 ’-tosylamino-3 ’-phenyl)propyl-L-alaninate, 82.- Acetic 
anhydride (0.33 ml, 3.44 mmol) was added dropwise with stirring to a solution of t- 
butyl 2’(S)-N-(2,-tosylamino-3,-phenyl)propyl-L-alaninate, 79 (1.49 g, 3.44 mmol) 
in pyridine (10 ml). The mixture was stirred at room temperature under an atmosphere 
of nitrogen for 3h before being dissolved in dichloromethane, washed with 1M 
hydrochloric acid, a 10% sodium hydroxide solution and water. The organic layer 
was then dried over sodium sulphate, filtered and the dichloromethane removed in 
vacuo. The crude product was purified by column chromatography (ethyl acetate- 
pentane, 1:4 to 1:2), leaving 82 (1.14 g, 70%) as a colourless oil; Rf 0.28 (ethyl
-100-
acetate-pentane, 1:2); [a]D +65.0 (c 1.29, CH2CI2). Found: C, 63.1; H, 7.4; N, 
5.9; S, 6.5. C25H34N2 O5S requires: C, 63.3; H, 7.2; N, 5.9; S, 6.75%. vmax 
(KBr)/cm-l 1735 (COOtBu), 1635 (COCH3), 1335 & 1165 (S02N)- (CDCI3) 
0.74 (3H, d, /  8 , CHC//3), 1.33 (9H, s, C(C//3)3), 1.86 (3H, s, COCH3 ), 2.41 
(3H, s, PhC//3 ), 2.62 - 2.68 (2H, m, CHjPh), 3.15 (1H, dd, J  4, -14, HC//N), 
3.32 - 3.40 (1H, m, C//CH2Ph), 3.78 (1H, dd, J  10, -14, HC//N), 3.84 (1H, q, /  
8 , C //CH 3), 6.74 (1H, d, /  4, NH), 7.15 - 7.28 (7H, m, ArH), 7.70 (2H, d, /  8, 
Ar//). 9 c  (CDCI3) 15.30 (CHCH3), 21.37,21.88 (CH3), 27.66 (C(CH3)3), 41.78, 
45.38 (CH2 ), 57.34, 58.33 (CH), 82.51 (C(CH3)3), 126.51, 126.60, 127.11,
128.48, 129.19 (Ar-CH), 137.48, 137.64,142.80 (ArC), 169.76, 174.16 (CO), mlz 
(FAB) 475 ([M+H]+, 8%), 419 ([M-<Bu]+, 100).
N fO-Di-tosyl-L-alaninol> 84.- A solution of L-alaninol (1.26 g, 16.8 mmol) and 
pyridine (8.15 ml, 101 mmol) in dichloromethane (8 ml) was added dropwise at 0°C 
to tosyl chloride (12.8 g, 67.2 mmol). The mixture was stirred under an atmosphere 
of nitrogen at 0 °C for lh then at room temperature for a further 2h before being 
quenched by the addition of water and extracted with dichloromethane. The combined 
extracts were washed with 2M hydrochloric acid, saturated sodium hydrogen 
carbonate solution and water, then dried over sodium sulphate, filtered and 
concentrated in vacuo, leaving a crude oil which was purified by column 
chromatography (ethyl acetate-petroleum ether, 1:9 to 1:2) to give 84 (5.07 g, 79%) as 
a colourless solid, mp 95 - 98 °C (lit.,135 104 - 105°C); Rf 0.36 (ethyl acetate- 
petroleum ether, 1:2); [a]D -36.2 (c 1.36, CH2CI2) [lit. , ^ 5 -38.2 (c 1.02, CHCI3)]. 
Found: C, 53.1; H, 5.5; N, 3.6. C17H21NO5 S2 requires: C, 53.25; H, 5.5; N, 
3.65%. Vmax (C D C ^ /c n r1 3295 (NH), 1355 (ArS0 2 N), 1167 (OS02). 9 h  
(CDC13) 1.08 (3H, d, J  7, CHC//3), 2.43 (3H, s, PhC//3), 2.46 (3H, s, PI1C //3),
3.54 - 3.60 (1H, m, C//CH3), 3.84 (1H, d d ,/4 , -10, HCZ/OSO2), 3.93 (1H, dd, /  
4, -10, HC//OSO2), 4.73 (1H, d, J  8, NH), 7.32 (4H, d, J  8, ArH), 7.72 (4H, d, J  
8, Ar//). 9 c  (CDCI3) 17.82 (CHCH3), 21.46 & 21.61 (CH3Ar), 48.27 (CHCH3),
-101-
72.37 (CH2 OSO2), 126.93, 127.86, 129.71, 129.91 (Ar-CH), 132.21, 137.28, 
143.57, 145.12 (ArC). mlz (FAB) 384 ([M+H]+, 100%).
t-Butyl 2'(S)-N-(2'-tosylamino)propyl-L-alaninate, 85.- The hydrochloride salt of 
L-alanine /-butyl ester (0.12 g, 0.67 mmol) and triethylamine (0.26 ml, 1.83 mmol) 
were added to a solution of N,0-di-tosyl-L-alaninol, 84 (0.23 g, 0.61 mmol) in DMF 
(2 ml). The mixture was stirred at room temperature under an atmosphere of nitrogen 
overnight before being dissolved in ethyl acetate. The solution was washed with 
water, dried over sodium sulphate, filtered and the ethyl acetate removed in vacuo. 
The crude product was purified by column chromatography (ethyl acetate-petroleum 
ether, 1:4 to 1:1), leaving 85 (0.08 g, 36%) as a colourless oil; Rf 0.18 (ethyl acetate- 
petroleum ether, 1:2); [a]D +5.12 (c 0.98, CH2CI2). Found: C, 57.6; H, 8.0; N, 
7.8. C17H28N2O4S requires: C, 57.3; H, 7.9; N, 7.9%. Vmax (CDCl3)/cm-l 3276 
(NH), 1727 (CO), 1366, 1159 (SO2N). 9 h  (CDCI3) 1.12 (3H, d , / 7 ,  CHCH3), 
1.18 (3H, d, 7 7, CHCH3 ), 1.44 (9H, s, C(CH3 )3), 2.23 (1H, dd, J  8 , -12, 
HCHNH), 2.43 (3H, s, CH3PI1), 2.65 (1H, dd, J  8, -12, HCHNH), 3.06 (2H, q, J  
7, 2 X CHCH3), 5.40 (1H, br s, NH), 7.30 (2H, d, J  8, ArH), 7.76 (2H, d, J  8 , 
ArH). 9 c  (CDCI3) 19.26, 19.57 (CHCH3), 21.75 (PI1CH3), 28.29 (C(CH3)3). 
49.86 (CH), 52.61 (CH2), 57.48 (CH), 81.46 (C(CH3)3), 127.49, 129.83 (Ar-CH), 
137.47, 143.47 (ArC), 175.04 (CO), mlz (FAB) 357 ([M+H]+, 100%).
2-(S)-Methyl-l-tosyl-aziridine, 86.- Triethylamine (0.26 ml, 1.87 mmol) was added 
dropwise with stirring to a solution of N,0-di-tosyl-L-alaninol, 84 (0.72 g, 1.87 
mmol) in dichloromethane (5 ml). The mixture was stirred at room temperature under 
an atmosphere of nitrogen overnight and then washed with 2M hydrochloric acid and 
water, dried over sodium sulphate, filtered and concentrated in vacuo. The crude 
product was purified by column chromatography (ethyl acetate-petroleum ether, 1:4) 
to give 86 (0.20 g, 50%) as a colourless solid, mp 56 - 58 °C (lit.,*20 60 - 61 °C); 
Rf 0.29 (ethyl acetate-petroleum ether, 1:4); [a]D +28.6 (c 0.89, CH2CI2). Found:
-102-
C, 56.8; H, 6.2; N, 6.5. C10H 13NO2S requires: C, 56.85; H, 6.2; N, 6.6%. vmax 
(CDCl3)/cm-l 1302, 1149 (SO2N). 9h  (CDCI3) 1.26 (3H, d, J  6, CHCH3), 2.03 
(1H, d, J  5, HC//N), 2.45 (3H, s, C//3PI1), 2.61 (1H, d, J  7, HCHN), 2.80 - 2.86 
(1H, m, CH), 7.34 (2H, d, /  8, ArH), 7.83 (2H, d, J  8, AiH). d c  (CDCI3) 16.79 
(CHCH3), 21.64 (CH3Ph), 34.73 (CH2), 35.86 (CH), 127.80, 129.70 (Ar-CH),
135.31, 144.42 (ArC). mlz (FAB) 212 ([M+H]+, 81%).
t-Butyl 2'(S)-N-(2 '-tosylamino)propyl-L-alaninate, 85.- 2-(S)-Methyl-l-tosyl- 
aziridine, 86 (43 mg, 0.21 mmol) was dissolved in DMF (2 ml). The hydrochloride 
salt of L-alanine f-butyl ester (42 mg, 0.23 mmol) and triethylamine (0.09 ml, 0.63 
mmol) were added and the mixture was stirred at room temperature under an 
atmosphere of nitrogen for 48h. The mixture was then dissolved in ethyl acetate, 
washed with water, dried over sodium sulphate, filtered and the ethyl acetate removed 
in vacuo. The crude product was purified by column chromatography (ethyl acetate- 
petroleum ether, 1:2), leaving 85 (23 mg, 31%) as a colourless oil. Data as above.
t-Butyl N-benzyloxycarbonyl-2'(S)-N-(2 '-tosylamino)propyl-L-alaninate, 87. - 
Benzyl chloroformate (0.35 ml, 2.48 mmol) and triethylamine (0.35 ml, 2.48 mmol) 
were added dropwise simultaneously to a stirred solution of r-butyl 2f(S)-N-(2- 
tosylamino)propyl-L-alaninate, 85 (0.22 g, 0.62 mmol) in toluene (5 ml). The 
mixture was stirred at 70 °C under nitrogen for 18h before being dissolved in 
dichloromethane, washed with 1M hydrochloric acid and water, dried over sodium 
sulphate, filtered and concentrated in vacuo to leave a crude oil which was purified by 
column chromatography (ethyl acetate-petroleum ether, 1:9 to 1:4), leaving 87 (0.17 
g, 58%) as a colourless oil; Rf 0.40 (ethyl acetate-petroleum ether, 1:4); [a]D *28.1 
(c 2.54, CH2CI2 ). Found: C, 61.3; H, 6.8; N, 5.5. C25H34N2O6S requires: C, 
61.2; H, 7.0; N, 5.7%. Vmax (CDC^/cm *1 1731 (COOteu), 1702 (COOCH2Ph), 
1331, 1155 (SO2N). 9H (DMSO, 100 °C) 0.93 (3H, d, /  7, CHCH3), 1.27 (3H, d, 
J  7, CHCH3 ), 1.30 (9H, s, C(CH3)3), 2.35 (3H, s, PhC//3), 3.12 (1H, dd, J  6 ,
-103-
-14, HCi/N), 3.21 (1H, dd, J  8, -14, HCi/N), 3.39 - 3.46 (1H, m, CH), 4.05 (1H, 
q, J  7, CH), 4.99 (1H, d, J  -13, HC//Ph), 5.08 (1H, d, /  -13, HCi/Ph), 7.13 (1H, 
br s, NH), 7.27 - 7.35 (7H, m, AiH), 7.65 (2H, d, J  8, Ari/). d c  (DMSO, 100 <>C) 
14.65, 17.92 (CHCH3), 20.22 (PhCH3), 27.05 (C(CH3)3), 48.30 (CH), 51.88 
(CH2N), 56.58 (CH), 66.05 (CH2Ph), 80.12 (C(CH3)3), 125.86, 126.94, 127.17,
127.67, 128.84 (Ar-CH), 136.10, 138.79, 141.84 (ArC), 155.17 (OCON), 169.84 
(COOtBu). mlz (FAB) 491 ([M+H]+, 60%), 435 ([M-*Bu]+, 44).
N -B en zy lo xyca rb o n y l-2 ,(S )-N -(2 f-to sy lam ino )-p ropy l-L -a lan ine , 91 .- 
Trifluoroacetic acid (0.32 ml, 4.14 mmol) was added dropwise with stirring to a 
solution of f-butyl N-benzyloxycarbonyl-2,(S)-N-(2’-tosylamino)propyl-L-alaninate, 
87 (0.26 g, 0.53 mmol) in dichloromethane (5 ml). The mixture was stirred at room 
temperature under an atmosphere of nitrogen for 3 days then concentrated in vacuo to 
give 91 (0.23 g, quantitative yield) as a colourless oil; Rf 0.58 (chloroform-methanol- 
acetic acid, 90:8:2); [cc]d -28.2 (c 0.97, CH2CI2). vmax (CH2 Cl2 ) /c n r l 3462 
(NH), 3058 - 2932 (COO//), 1670, 1682 (CO), 1325, 1158 (SO2N). du  (DMSO, 
100 OQ 0.95 (3H, d, J  1, CHCi/3 ), 1.32 (3H, d, /  7, CHCi/3 ), 2.38 (3H, s, 
C i/3Ph), 3.16 (1H, dd, /  7, -14, HCi/N), 3.26 (1H, dd, J  8, -14, HCi/N), 3.47 
(1H, q, /  7, C//CH3), 4.15 (1H, q, J 1, CHCH3), 5.05 (2H, d, J  6, C i/2Ph), 7.14 
(1H, d, /  8, NH), 7.29 - 7.38 (7H, m, Ari/), 7.66 (2H, d, J  8, AiH). d c  (DMSO, 
100 °C) 14.85, 17.92 (CHCH3), 20.28 (PI1CH3), 48.33 (CH), 51.95 (CH2N), 
55.81 (CH), 66.07 (CH2Ph), 125.87, 126.83, 127.15, 127.74, 128.87 (Ar-CH), 
136.15, 138.73, 141.89 (ArC), 155.00 (OCON), 172.23 (COOH). mlz (FAB) 435 
([M+H]+, 100%). Found: [M+H]+ 435.157135. C2 1 H2 7 N2 O 6S requires: 
435.158984.
N -Benzyloxy carbonyl-2 '(S)-N-(2’-tosylamino )propyl-L-alanine-N-methoxy-N- 
methylamide, 92.- N-Benzyloxycarbonyl-2f(S)-N-(2f-tosylamino)propyl-L-alanine, 
91 (1.81 g, 4.16 mmol) was dissolved in dichloromethane (35 ml). EDC (0.80 g,
-104-
4.16 mmol), N,0-dimethylhydroxylamine hydrochloride (0.45 g, 4.58 mmol) and 
triethylamine (0.64 ml, 4.58 mmol) were added and the mixture stirred at room 
temperature under an atmosphere of nitrogen for 24h. After this time, more EDC 
(0.80 g, 4.16 mmol), N,0-dimethylhydroxylamine hydrochloride (0.45 g, 4.58 
mmol) and triethylamine (0.64 ml, 4.58 mmol) were added and stirring was continued 
for a further 48h. The mixture was then washed with water, dried over sodium 
sulphate, filtered and concentrated in vacuo to leave a crude oil which was purified by 
column chromatography (ethyl acetate-petroleum ether, 1:4 to 1:1) to give 92 (0.35g, 
17%) as a colourless oil; Rf 0.41 (ethyl acetate-petroleum ether, 1:1); [<x]d +2.14 (c 
0.51, CH2 CI2). vmax (CH2Cl2)/cm-l 3238 (NH), 1694 (NCOO), 1673 (CON), 
1324, 1154 (SO2N). 9 h  (DMSO, 100 °C) 0.96 (3H, d, J  6 , CHCH3), 1.23 (3H, d, 
J  7, CHCH3 ), 2.39 (3H, s, PhCf/3 ), 3.08 (3H, s, NCH3 ), 3.25 (2H, d, J  7, 
C //2N), 3.51 - 3.57 (1H, m, CHCH3), 3.58 (3H, s, OCH3), 4.74 - 4.82 (1H, m, 
CHCH3), 5.01 - 5.09 (2H, m, Ctf2Ph), 7.15 (1H, d, J  7, NH), 7.32 - 7.40 (7H, m, 
ArH), 7.67 (2H, d , / 8, ArH). 3 c  (DMSO, 100 °C) 14.41, 18.14 (CHCH3), 20.22 
(PhCH3), 31.76 (NCH3), 48.44 (CH), 48.83 (CH2N), 51.53 (CH), 60.35 (OCH3), 
66.24 (CH2Ph), 125.89, 127.10, 127.26, 127.70, 128.80 (Ar-CH), 136.01, 136.68,
141.77 (ArC), 155.48 (NCOO), 171.69 (CON), mlz (FAB) 476 ([M-H]-, 100%). 
Found: [M+H]+478.199394. C23H32N3O6S requires: 478.201183.
N-Acetyl-2 '(S)-N-(2'-tosylamino-3'-phenyl)propyl-L-alanine, 93.- Trifluoroacetic 
acid (0.61 ml, 8.08 mmol) was added dropwise with stirring to a solution of /-butyl 
N-acetyl-2,(S)-N-(2’-tosylamino-3,-phenyl)propyl-L-alaninate, 82 (0.96 g, 2.02 
mmol) in dichloromethane (15 ml). The mixture was stirred at room temperature 
under an atmosphere of nitrogen for 3.5h before being concentrated in vacuo to leave 
a crude oil which was triturated with ethyl acetate. The resulting product was 
recrystallised from ethyl acetate-petroleum ether leaving pure 93 (0.48 g, 57%) as a 
colourless solid, mp 201 - 202 °C; Rf 0.56 (chloroform-methanol-acetic acid, 90:8:2); 
[<x]d -28.6 (c 2.16, CH3OH). Found: C, 60.25; H, 6.2; N, 6 .6 . C21H26N2 O5S
-105-
requires: C, 60.3; H, 6.3; N, 6.7%. Vmax (KBrycnr1 3358 (NH), 1729 (COOH), 
1606 (COCH3), 1342 & 1160 (SO2N). 3h  (DMSO, 160 °C) 1.20 (3H, d, 7 7, 
CHCH3), 1-89 (3H, s, COCH3), 2.34 (3H, s, CH3 A1), 2.68 (1H, dd, 7 7, -14, 
HCHN), 2.79 (1H, dd, 7 6, -14, HCHN), 3.23 (1H, dd, 7 6 , -15, HCHPh), 3.42 
(1H, dd, 7  8, -15, HCHPh), 3.61 (1H, m, CHCH3), 4.23 (1H, q, 7  7, CHCH2Ph), 
7.07 - 7.16 (5H, m, ArH), 7.21 (2H, d, 7 8 , ArH), 7.50 (2H, d, 7 8 , ArH). d c  
(DMSO, 160 °C) 14.52 (CHCH3), 20.04,20.90 (CH3), 38.34, 38.53 (CH2), 55.19, 
55.58 (CH), 125.40, 125.78, 127.41, 128.45, 128.62 (Ar-CH), 137.40, 138.42, 
141.73 (ArC), 171.10, 172.00 (CO), mlz (FAB) 419 ([M+H]+, 100%).
N-Acetyl-2'(S)-N-(2 ’-tosylamino-3 '-phenyl)propyl-L-alanine-N-methoxy-N- 
methylamide, 94.- N-Acetyl-2,(S)-N-(2,-tosylaimno-3'-phenyl)propyl-L-alanine, 93 
(0.62 g, 1.48 mmol) was dissolved in DMF (25 ml). EDC (0.28 g, 1.48 mmol), 
N,0-dimethylhydroxylamine hydrochloride (0.16 g, 1.63 mmol) and triethylamine 
(0.23 ml, 1.63 mmol) were added to the solution and the mixture was stirred at room 
temperature under an atmosphere of nitrogen for 48h. After this time, more EDC 
(0.28 g, 1.48 mmol), N,0-dimethylhydroxylamine hydrochloride (0.16 g, 1.63 
mmol) and triethylamine (0.23 ml, 1.63 mmol) were added and the mixture was 
stirred for a further 48h before being dissolved in ethyl acetate, washed with water, 
dried over sodium sulphate, filtered and concentrated in vacuo leaving a crude oil 
which was purified by column chromatography (ethyl acetate-petroleum ether, 1:1 to 
ethyl acetate) to give 94 (0.31 g, 46%) as a colourless oil; Rf 0.34 (ethyl acetate); 
[a]D +34.5 (c 0.79, CH2CI2). Vmax (CH2Cl2)/cm- 1 3464 (NH), 1666, 1643 (CO), 
1329, 1158 (SO2N). 3h  (DMSO, 160 °C) 1.14 & 1.28 (3H, d, 7 7, CHCH3), 1.91 
& 1.93 (3H, s, COCH3 ), 2.33 & 2.34 (3H, s, PhCH3 ), 2.56 - 2.78 (2H, m, 
CH2N), 3.06 & 3.07 (3H, s, NCH3), 3.25 - 3.48 (2H, m, CH2Ph), 3.64 & 3.67 
(3H, s, NOCH3), 3.69 - 3.75 (1H, m, CH), 4.83 - 4.86 (1H, m, CH), 6.87 (1H, br 
s, NH), 7.02 - 7.23 (7H, m, ArH), 7.47 - 7.52 (2H, m, ArH). d c  (DMSO, 160 °C) 
14.23 & 14.97 (CHCH3), 19.80, 20.79 (CH3), 31.67, 38.88 (CH2 ), 47.10, 50.71
-106-
(CH), 54.86 (NCH3), 60.22 (OCH3), 125.12, 125.58, 127.15, 128.29, 128.38 (Ar- 
CH), 137.10,138.52, 141.42 (ArC), 170.71,171.42 (CO), m/z (FAB) 460 ([M-HJ* 
, 100%). Found: [M+H]+ 462.202332. C23H32N3O5S requires: 462.206268.
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